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Abstract 
In this study, I characterised mice lacking the transmembrane adaptor protein SIT. I 
found that the loss of SIT resulted in altered T-cell development. Indeed, thymocytes 
deficient for SIT displayed a more activated phenotype and an enhanced positive 
selection that was even partially converted to negative selection in HY and P14 TCR 
transgenic mice. However, SIT-/- mice expressing a TCR with high affinity, such as 
OT-I, did not show any alteration of T-cell development. This indicates that the ability 
of SIT to regulate thymic selection processes is dependent on TCR affinity. 
Moreover, SIT knockout mice displayed a decreased number of SP thymocytes as 
well as a decreased proportion of recent thymic emigrants in the periphery. In 
addition, further investigation revealed that SIT-/- mice have strongly reduced number 
of naïve CD8+ T cells. We showed that the loss of naïve CD8+ T cells is neither due 
to a survival defect nor to enhanced apoptosis but it is partially caused by a reduction 
in the generation of T-cell precursors in the thymus. Moreover, SIT-deficient mice 
progressively accumulate CD44hiCD8+ cells in the periphery. A more detailed 
characterisation of those cells revealed that they closely resemble lymphocytes 
undergoing homeostatic proliferation. To directly test the role of SIT in T-cell 
homeostasis, I performed adoptive transfer experiments by injecting CFSE labelled 
lymph node cells from MHC-I restricted transgenic mice with low (HY), intermediate 
(P14) and with high (OT-I) TCR affinity into lymphopenic hosts. Strikingly, loss of SIT 
results in homeostatic expansion of HY transgenic T cells that normally do not 
undergo homeostatic proliferation in lymphopenic hosts. Similarly, SIT-/-P14 T cells 
showed a more accelerated homeostatic expansion upon adoptive transfer into 
lymphopenic recipients as compared to SIT+/+P14 cells. Similar to T-cell 
development, lymphopenia-induced proliferation of OT-I CD8+ T cells was not 
affected by the loss of SIT. These results clearly indicate that SIT is a potent negative 
regulator of both T-cell development and homeostasis. Our data also demonstrate 
that the reduced number of naïve CD8+ T cells in SIT-deficient mice is likely due to 
an accelerated homeostatic expansion. During this process, CD8+ T cells acquire 
CD44hi expression. In addition to defective T-cell development and homeostasis, SIT-
/- T cells are hyperreactive to TCR-mediated stimuli in vitro and develop more severe 
EAE. Collectively, these observations clearly indicate that loss of SIT results in a 
lowered threshold of activation in both thymocytes and T cells. Despite the fact that 
SIT-deficient mice displayed a perturbed T-cell homeostasis, loss of SIT did not 
result in any obvious sign of altered immune function in young mice. Thus, we 
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hypothesised a presence of a compensatory mechanism(s) that would prevent SIT 
deficient T cells from becoming fully activated. 
Indeed, I showed that SIT-/- CD8+ T cells develop sensory adaptation by adjusting 
coreceptor and CD5 expression. Moreover, additional data from our laboratory 
showed that in vitro Zap-70 activity is severely impaired in SIT deficient T cells. It is 
likely that compensatory mechanism(s) present in SIT-/- T cells is (are) sufficient to 
prevent T cells from becoming fully activated. However, this mechanism fails to 
prevent altered T-cell development, lowered threshold of activation as well as altered 
peripheral T-cell homeostasis. 
Collectively, I showed that SIT acts as a negative regulator of T-cell development and 
homeostasis by modulating TCR signalling threshold. 
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Reagents and recipes 
PCR reagents 
Taq Polymerase (Qiagen) 
Deoxynucleotide (dNTP) Solution Mix (Qiagen) 
Enhancer Q solution (Qiagen) 
MgCl2 (Qiagen) 
10xTaq Buffer (Qiagen) 
DMSO (dimethyl-sulfoxide, Sigma) 
Agarose gel (2%) 
2g agarose (PeqLab) 
100ml 1xTAE buffer 
10µl etidium bromide (Roth) 
50xTAE buffer ( 1l ) 
242g Tris base (Roth) 
57.1ml acetic acid (Baker) 
100ml 0.5M EDTA (Sigma) pH 8.0  
DNA 6x loading buffer, blue: 
0.2g bromphenol blue (Roth) 
0.2g xylencyanol 
1ml EDTA (500mM) 
6ml glycerin (87%) 
2ml distilled H2O (dH2O) 
Cell culture/Mouse Medium: 
RPMI 1640 (Biochrom) supplemented with: 
10% heat deactivated FCS (Fetal Bovine Serum, PAN Biotech) 
2-β mercaptoethanol (50µM) (Sigma) 
Antibiotics: Penicillin/Streptamycin (Roth) 
Lysis buffer  
1% NP-40 (Nonidet P-40, Igepal, Sigma) 
1% LM (laurylmaltoside) (Calbiochem) 
1mM sodium monovanadate (Merck) 
1mM PMSF (phenilmethylsulfonyl fluoride, Sigma) 
50mM Tris (ph:7.5) (Roth) 
10mM NaF (Sigma) 
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10mM EDTA ( ph 7.5) (Sigma) 
166mM NaCl  (Roth) 
657µl (dH2O) 
NP-40 washing buffer 
1% 0.5M EDTA (Sigma) 
5% 1M Tris pH7.4 (Roth) 
5% NP-40 (Igepal, Sigma) 
15% 1M NaCl (Roth) 
5x reducing sample-buffer (for 10 ml) 
5ml glycerol (Sigma) 
2ml 0.5M Tris, pH 6.8 (Roth) 
2.5 ml 20% SDS (Calbiochem) 
0.25ml 10% bromphenol blue (Roth) 
50l 2-β-mercaptoethanol (Sigma) 
Gel electrophoresis and Western blot 
SDS-PAGE gel (for 5 ml, 10% separating gel) 
2.1ml (dH2O) 
1.6ml 30% acrylamide/BIS (Bio-Rad) 
1.23 ml 1.5M Tris-HCl pH8.8 (Roth) 
49.2µl 10% SDS (Calbiochem) 
24.6µl 10% APS (Ammoniumperoxidisulphate, Roth) 
2.46µl TEMED (Roth) 
SDS-PAGE gel (for 2 ml stacking gel) 
1.2ml (dH2O) 
0.375ml 40% acrylamide/BIS 29:1 (Bio-Rad) 
0.5ml 0.5M Tris-HCl pH6.8 (Roth) 
20µl 10% SDS (Calbiochem) 
20µl 10% APS (Roth) 
2µl  TEMED (Roth) 
Transblot solution (for 1l) 
5.80g Tris (Roth) 
2.90g glycine (Roth) 
0.37g SDS (Calbiochem) 
200ml methanol (Roth) 
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10xTBS buffer (for 1l) 
80.0g NaCl (Roth) 
2.0g KCl (Sigma) 
30.0g Tris (Roth) pH 8.00 
Stripping buffer (for 200ml) 
40.0ml 10% SDS (Calbiochem) 
1.4ml 2-β-mercaptoethanol (Sigma) 
25.0ml 0.5M Tris, pH 6.7 (Roth) 
Others 
10xTGS - electrophoresis buffer for SDS-PAGE gel (Bio-Rad) 
Tween-20 (Roth) 
Protein MW standard: All Blue (BioRad) 
DNA: PeqGold Leiter mix (Peqlab) 
ECL  Kit (Amersham) 
PBS Dulbecco’s (Gibco)  
BSA (albumine, bovine serum, fraction V, Sigma) 
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Materials and methods 
Mice 
The targeting construct to inactivate sit gene was generated by Dr. Eddy Bruyns. SIT 
knockout mice were generated by Prof. Klaus Pfeffer as previously described (4). 
Animals containing the disrupted SIT allele were backcrossed onto C57BL/6 (Charles 
River) for more than 10 generations. OT-I and OT-II TCR transgenic mice were kindly 
provided by Dr. Percy Knolle, P14 by Dr. Thomas Kammerthoens, and HY TCR 
transgenic mice were kindly provided by Dr. Gary Koretzky. For TCR transgenic 
studies, SIT-/- mice  TCR tg mice were obtained by crossing SIT-/- mice with SIT+/- 
TCR heterozygote transgenic mice. B6.SJL CD45.1+ recipient mice for adoptive 
transfer experiments were kindly provided by Dr. Dirk Schlüter. 
Mice genotyping 
Genotypes of mice were assessed by standard PCR. Total genomic DNA was 
purified from mouse tails by using DNeasy Tissue Kit (Qiagen Cat. Nr. : 69506). For 
PCR reactions, (for details see Appendix) primers were obtained from BioTeZ Berlin-
Buch GmbH). 
Primers used for genotyping  
SIT primers 5´>>3´: primer 1 ( CCT GAC TCT CAC ACC AGC AGC ), primer 2 (GGT 
CCA CTG GGA CAA GAG TGC AGC C), primer 3  (GAC GTG CTA CTT CCA TTT 
GTC ACG TCC), HY primers 5´>>3´: pimer 1 (GCT TTG AGG CCG AGT TTA GG), 
primer 2 (GCT CAC TGT CAG CTT TGT CC), OT-II primers 5´>>3´:  primer 1 (AAA 
GGG AGA AAA AGC TCT CC), primer 2 (ACA CAG CAG GTT CTG GGT TC), 
primer 3 (GCT GCT GCA CAG ACC TAC T), primer 4 (CAG CTC ACC TAA CAC 
GAG GA), OT-I primers 5´>>3´:  primer 1 (TTG AGA GCT GTC TCC), primer 2           
(AAG GTG GAG AGA GAC AAA GGA TTC), primer 3 (GTC AGT CGA GTG CAC 
AGT TT) primer 4 (CCA ATG TTG CTT GTC TGG TG), P14  primers 5´>>3´:   primer 
1 (CTG ACC TGC AGT TAT GAG GAC AGC AC), primer 2 (CGA GGA TCC TTT 
AAC TGG TAC ACA GCA GG) Rag1 primers 5´>>3´: primer 1 (TGG ATG TGG AAT 
GTG TGC GAG), primer 2 (GAG GTT CCG CTA CGA CTC TG), primer 3 (CCG GAC 
AAG TTT TTC ATC GT).   
 7 
 
Single cell suspension 
Lymphoid organs (thymus, lymph nodes or spleen) were removed from sacrificed 
wild-type and SIT deficient mice and placed into Petri dishes filled with PBS. 
Subsequently organs were mechanically disrupted and filtered through nylon mesh 
with 70-µm pore size.  Finally, cells were washed in PBS (1500rpm, 4°C, 10 min) and 
resuspended either in medium or in PBS. When it was required, all steps were 
performed under laminar flow to maintain sterile conditions. 
T-cell purification 
For standard T-cell purification, spleens from sacrificed mice were removed and 
single cell suspensions were prepared. T-cell purification was carried out by using 
Mouse Pan T cell Isolation Kit (Miltenyi Biotech, Order Nr.: 130-090-861) according 
to the manufacturer’s instructions. Purity of cell preparations was assessed by flow 
cytometry (CD3 and TCR-β stainings) and was routinely >95%. 
Proliferation assay and cytokine determination 
Purified T cells (2.5104 cells/well) were cultured in RPMI medium (supplemented 
with 10% FCS, antibiotics and 2-β-mercaptoethanol) in U-bottomed 96 well plate 
(Costar) at 37°C, 5%CO2 in a humidified atmosphere,  in the presence of plate bound 
anti-mouse CD3ε (clone: 145-2C11, BD Biosciences) or PMA and ionomycin. Cells 
were cultured for 72 hours and labelled with 0.5 μCi/well [3H]-thymidine during the 
last six hours of culture. Supernatants from anti-CD3 stimulated T cells were 
collected after 48 hours and cytokine level was assessed by cytometric bead array 
(CBA, BD Biosciences). 
Irradiation and adoptive transfer 
Single cell suspensions were prepared from lymph nodes of donor mice. Cells were 
washed (1500rpm, 4°C, 10 min) in PBS, counted and resuspended in ice cold PBS at 
5x106 cells/ml. CFSE (Sigma) was added to the cells at 0.2µM final concentration.  
Samples were incubated at 37°C for 10 min then, washed twice in ice cold PBS 
supplemented with 5% FCS (1500rpm, 4°C, 10 min). Subsequently cells were 
resuspended in PBS for intravenous injection at 10x106/ml concentration. Adoptive 
transfer was performed by injecting 200µl (2x106 cells) of cell suspension into the 
lateral tail vein of B6.SJL CD45.1+ recipient mice. Recipient mice were irradiated 
(dosage: 950rad) one day before adoptive transfer by using BioBeam 8000 (STS 
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Steuerungstechnik & Strahlenschutz GmbH, 38110 Braunschweig, Germany). During 
the entire experiment recipient mice were kept on 2mg/ml neomycin sulphate (Sigma, 
Cat. Nr.: N6386-25G) supplied in the drinking water. Mice were analyzed at day 3 or 
day 7 after adoptive transfer.  
In vitro cytokine stimulation 
Lymph node cells were loaded with CFSE (as described above) and washed twice in 
PBS. Pellets were resuspended at 5x106/ml concentration in mouse medium (for 
details see reagents and recepies) and cultured in 48-well plates (Costar) at 2x106/ml 
concentration. Cultured cells were either treated with recombinant mouse IL-7 or IL-
15 (R&D Biosystems GmbH) at 100ng/ml final concentration or left untreated. After 
72 hours of incubation at 37°C, in a humidified 5% CO2 atmosphere cells were 
harvested and subsequently stained for with CD4 and CD8 antibodies. CFSE profiles 
of gated CD8+ cells were analysed by flow cytometry. 
Flow Cytometry 
For FACS analyses single cell suspensions were prepared and typically 1106 cells 
were stained with the indicated antibodies and subsequently analysed on a FACS 
Calibur using CellQuest software (Becton Dickinson). All antibodies were purchased 
from BD Biosciences (for more information about antibodies used in this study see 
Appendix-I). For homeostatic proliferation experiments, single cell suspensions of 
lymph node and spleen cells from recipient mice were prepared and 1-3x106 cells 
were stained with the indicated antibodies. 
Intracellular Bcl-2 FACS staining 
Lymph nodes were isolated from wild-type and SIT-knockout mice and single cell 
suspensions were prepared. Subsequently, 1.5x106 cells were stained with CD8-PE 
antibody. Cell fixation and permeabilization was performed by using Fix. and Perm., 
solutions from Invitrogen (Cat. Nr.: GAS-004). Bcl-2 intracellular staining was carried 
out by using Bcl-2-FITC Antibody Reagent Set (BD Biosciences Cat. Nr: 554221) 
according to the manufacturer`s instructions.  
BrdU administration and staining protocol 
BrdU (Sigma) was administrated in sterile drinking water at 0.8mg/ml  for 7 days and 
was supplemented with 2% glucose. BrdU solution was prepared daily. Following 
BrdU administration, wild-type and SIT-knockout mice were sacrificed and single cell 
suspensions were prepared from lymph nodes and spleens as described previously. 
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Typically, 3x106 cells were stained with CD4 and CD8 antibodies. Subsequently, 
intracellular staining to determine BrdU incorporation was carried out by using BrdU 
Flow Kit (BD Biosciences) according to the manufacturer`s instructions.  
Statistics 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., 
San Diego, CA). Asterisks represent p<<0.05 values calculated by unpaired two-
tailed Student´s t test. 
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1. Introduction 
1.1. The immune system 
Living organisms make an “endless” number of interactions with their environment 
during the course of their life. These interactions serve as the basis for survival and  
reproduction, and are therefore indispensable. On the other hand, there are number 
of dangerous agents such as parasites, bacteria and viruses from which an organism 
must defend itself to maintain its integrity. Our immune system protects us from 
pathogens and is ready to prevent any infections that might have serious or life-
threatening consequences. A very important requirement that enables the immune 
system to function is the ability to recognise and differentiate non-self as potentially 
dangerous from self that is harmless. Proper immune function requires a magnificent 
and tightly controlled orchestra of numerous participants. In vertebrates, the immune 
system can be divided into two main components: innate and adaptive immunity. 
Phylogenetics show adaptive immunity evolved more recently when compared with 
innate immunity. The cooperation between innate and adaptive immunity results in a 
well controlled immune response. The components of innate immunity are 
macrophages, dentritic cells, NK cells, and the complement system. Innate immunity 
is characterised by an immediate reaction, lack of specificity and the absence of 
immunological memory. In contrast to the innate immune system, the adaptive 
immune system possesses some more distinctive functions such as immunological 
memory and specificity. These features allow adaptive immunity to improve its 
protective function following recurrent infections. These advanced functions of 
adaptive immunity are provided by two main cell types namely, T and B lymphocytes. 
During immune response, innate immunity represents the first line of defense and 
provides an alarm signal to the adaptive immune system to induce a highly specific 
and more effective immune response. Here I am going to introduce those 
components of the adaptive immune system that are of relevance for better 
understanding my work (1, 46). 
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1.2. T lymphocytes (Thymus-derived lymphocytes) 
1.2.1. Early T-cell development  
During embryonic life, all haematopoietic cells are generated in the embryonic spleen 
and liver. At later developmental stages, lymphoid progenitor cells are generated in 
the bone marrow. From the bone marrow, progenitor cells migrate via the blood 
stream to the thymus to complete their maturation and become T lymphocytes. Once 
they are in the thymus, they become irreversibly committed toward the T-cell lineage. 
This process is largely dependent on Notch1 receptor signalling (89). Further 
development of T cells occurs in an ordered progression (summarized in Figure 1) 
that can be divided into discrete developmental stages defined by the expression of 
the CD4 and CD8 costimulatory molecules.  Most immature T-lymphocyte precursors 
do not express either CD4 or CD8 and are therefore called DN (double negative 
CD4-CD8-) thymocytes. These cells further mature into the DP (double positive) 
stage (CD4+CD8+) as they express both CD4 and CD8. At the DP stage, thymocytes 
undergo a selection process. At the end of the selection process, only less than 5% 
complete their maturation as CD4+ or CD8+ T cell. Double negative thymocytes are 
heterogeneous and can be further divided into more distinct subsets that are defined 
by the expression of CD44 and CD25 (IL2R alpha): DN1 (CD44+CD25-), DN2 
(CD44+CD25+), DN3 (CD44-CD25+), DN4 (CD44-CD25-) (34). Many efforts have 
been made to characterise more precisely DN thymocytes. These studies have 
revealed that DN1 and DN2 thymocytes do not express the CD3 complex and are 
CD4-CD8-CD3-. Thus, they are often termed as triple negative (TN) cells.  TN 
thymocytes express high levels of the receptor for stem cell-factor CD117/c-kit 
(hereafter referred to as CD117). Thymocytes that express high level of CD117 have 
a lymphoid restricted potential however, they are still capable of differentiating into B 
cells and NK cells as well as cells of the T lineage (16, 67). During the transition to 
the DN3 stage, DN2 thymocytes start to express T-cell specific components such as 
CD3 and in turn become CD117low. At this stage, they are fully committed toward the 
T-cell lineage.  Mice deficient for CD3ε show a developmental arrest at the DN3 
stage indicating the essential role of the CD3 complex to regulate further maturation 
of DN3 thymocytes (60). In addition to the CD3,  the proper rearrangement of the β 
chain of the TCR is required for further maturation. During transition from the DN3 to 
the DN4 stage an essential step named “β-selection” takes pace  that  in turn inhibits 
further DNA recombination at the TCRβ locus (allelic exclusion) (119). Allelic 
exclusion is induced by the successfully rearranged TCRβ chain that prevents any 
 12 
additional rearrangement at this site, thus, ensuring that only one kind of βTCR is 
expressed on the surface of each T cell.  
Thymocytes undergoing DN3>>DN4 transition do not express a functional αβTCR 
but instead they express a complex called pre-TCR. Similar to the TCR the pre-TCR 
coplex includes CD3εγ and εδ heterodimers as well as TCRδδ homodimer and a fully 
rearranged TCR β chain. Nonetheless, the pre-TCR does not contain the TCRα 
chain but a surrogate chain called pTα. No ligand for the pre-TCR has been identified 
so far. Thus, it has been suggested that the pre-TCR is able to signal in an MHC-
independent manner. Thymocytes expressing the pre-TCR complex also become 
CD117 negative indicating that they are fully committed to  the T-cell fate (16). In 
addition, the pre-TCR has been shown to translocate to the lipid rafts where it 
clusters with several molecules involved in T-cell signalling such as Lck and Zap70 
(2, 94, 102). Importantly, the pre-TCR-mediated signalling rescues DN thymocytes 
from apoptosis and induce proliferation (about 6-8 divisions) as well as further 
differentiation. Thus, any mutation resulting in an impaired signalling of the pre-TCR 
causes maturational arrest at the DN3 stage (75, 116). When β-selection is 
successfully completed thymocytes further mature from the DN4 to the DP stage. 
During this transition, recombination of the TCRα locus takes place. In parallel, 
upregulation of CD4 and CD8 occurs that results in the appearance of DP 
thymocytes that represent about 80-90% of the total thymic cell population. 
Thymocytes that express the fully assembled αβTCR undergo further selection steps. 
Those thymocytes that possess an altered αβTCR complex that is not capable of 
recognising self-peptide-MHC complexes or to induce proper signals are rapidly 
eliminated via a process termed  “death by neglect”  that applies to almost 90% of the 
thymocytes! Conversely, those thymocytes that possess a functional αβTCR undergo 
either positive or negative selection. Positive selection enables thymocytes to survive 
and to complete their developmental program to become T cells, whereas negative 
selection eliminates autoreactive thymocytes via apoptosis. 
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Figure 1. T cell development 
Main stages of T-cell development. Major selection events, surface, and intracellular 
molecules involved in T cell development are indicated. Abbreviations used in this 
figure: TN (triple negative), DN (double negative), DP (double positive), SP (single 
positive). 
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1.2.2. Positive and negative selection of thymocytes 
Both positive and negative selection require TCR:self-peptide-MHC contact in the 
thymus in order to “test” the affinity of the αβTCR complex to self-peptide-MHC. 
TCRs of immature DP thymocytes undergoing positive selection have low/moderate 
affinity to self-peptide-MHC complexes. On the contrary, thymocytes expressing a 
TCR with strong affinity to self-peptide-MHC ultimately die by negative selection. 
Self-peptide-MHC molecules are expressed on the surface of thymic stromal cells 
that are in tight contact with developing thymocytes. Thymocyte selection can be 
monitored by the expression of various surface markers. One protein that is 
immediately upregulated upon successful engagement with the appropriate self-
peptide-MHC is CD69. Expression of CD69 indicates that efficient signalling is 
generated via the TCR upon engagement with MHC molecules. However, the 
upregulation of CD69 does not correlate with TCR affinity. Thus, CD69 expression is 
induced by both positively and negatively selecting ligands and in turn indicates the 
activation status of thymocytes. Another very useful marker to investigate thymic 
selection is CD5, a negative regulator of TCR-mediated signalling (7, 103, 114). The 
expression of CD5 correlates with the signalling strength generated via the TCR. 
Therefore, analysis of CD5 expression has often been used as an indicator of TCR-
mediated signalling strength in several mouse models of thymic development (5-7, 
76, 114). Finally, the analysis of the expression of the αβTCR itself is also relevant 
for the investigation of selection events. Thymocytes that are positively selected such 
as βTCRhi can be distinguished from βTCRlo cells that are still immature or 
undergoing negative selection. In conclusion, thymocytes that express high level of 
CD5, CD69, and TCR will survive and complete their maturation program to become 
either MHC-I restricted or MHC-II restricted T cells. During thymic selection, the fate 
of developing T cells largely depends on the affinity of the TCR to self-peptide MHC.  
1.2.3. Molecular mechanisms of T-cell development 
Although, the general TCR affinity based model of T-cell development is widely 
accepted (Figure 2) little is known about the molecular mechanisms involved in 
thymocyte selection. Many efforts have been made to identify molecules that can be 
exclusively linked to either positive or negative selection processes. However, to date 
only calcineurin B1 and ERK were reported to be linked exclusively to the positive 
selection. Calcineurin B1 deficient mice show profound defects in positive selection. 
However, these cells undergo normal negative selection in various mouse models. 
Thus, calcineurin B1 seems to be involved in transmission of low affinity signals that 
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mediate positive selection (76). In addition, the different activation pattern of MAPKs 
is reported to regulate thymic selection processes. Though it is not entirely clear, but 
according to a currently proposed model, both the duration and the level of ERK 
activation is essential to mediate lineage comittement, positive selction but also 
involved in negative selection (3, 10, 11, 31, 62, 82).  Weak but sustained activation 
of ERK occurs upon low affinity interaction with self-peptide-MHC complexes and 
results in positive selection of thymocytes, whereas strong and transient ERK 
activation leads to negative selection (62, 66). In addition both the subcellular 
localisation and the kinetic of ERK activation were shown to be crutial in terms of 
determining selection outcome (24). Other MAPKs such as JNK (C-jun NH2-terminal 
kinase) have been shown to play a role in negative selection. Transgenic mice 
expressing a dominant negative form of JNK display an increased resistance to anti-
CD3-mediated depletion. This indicates that JNK is involved in deletion of 
thymocytes undergoing negative selection. This is further supported by the fact that 
JNK was shown to play a role in mediating apoptosis of various cell types (44, 92).   
Thymocytes undergoing negative selection are eliminated by apoptosis. Thus, pro- 
as well as anti-apoptotic molecules are also involved in regulating T-cell 
development. Upregulation of the antiapoptotic factor Bcl-2 was shown to be 
essential during positive selection as it partially rescues thymocytes from apoptosis. 
(12, 101, 105, 107). In addition, mice lacking the pro-apoptotic factor Bim showed a 
striking resistance to negative selection in various negative selection models (12). 
Other important players in mediating apoptosis are Bax and Bak that work in 
cooperation with Bim to mediate negative selection. Indeed, Bax/Bak double deficient 
mice show a marked resistance to both death by neglect as well as to antigen 
induced thymocyte deletion. In conclusion, at the end of thymic selection only those 
thymocytes survive that recognise self-peptide-MHC complexes with low/moderate 
affinity (thus are not autoreactive) but capable of fully reacting with foreign antigens 
(46, 91). 
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Figure 2. TCR affinity model of T cell development 
TCR affinity based model of T-cell development. The increasing colour intensity 
indicates increasing TCR affinity to self-peptide-MHC complexes. Selection 
outcomes induced by increasing TCR affinities are shown. 
 
1.3. TCR transgenic mouse models used in this study 
1.3.1. MHC-I restricted transgenic mouse models 
1.3.1.1. The HY model 
HY transgenic mice were generated in 1988 (50). These mice carry a TCR that 
selectively recognises the male specific antigen derived peptide HY (KCSRNRQYL) 
in the context of MHC class I H-2D.b In this system, transgenic T cells are committed 
to the CD8+ T-cell lineage (51, 115). 
The HY transgenic TCR consists of a TCRβ chain containing the Vβ8 region. The 
transgenic TCRαβ complex is recognised by the monoclonal antibody clone T3.70. 
Given the fact that the HY peptide is expressed only in male mice, this system is 
suitable to investigate both positive and negative thymic selection processes. (6, 26, 
51, 103, 115) In fact, in female mice where the HY peptide is not expressed, the 
transgenic TCR binds to self-peptide-MHC with low affinity, thus inducing positive 
selection. Conversely, in male mice that express the HY peptide negative selection 
takes place. 
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1.3.1.2. P14 transgenic mouse model 
P14 TCR transgenic mice were generated in 1989 (86). The P14 transgenic TCR is 
specific for the gp33 derived peptide KAVYNFATC (aa 33-41) of LCMV presented in 
the context of MHC-I H2-Db. Accordingly, T cells are committed to the CD8+ lineage. 
The transgenic TCR is composed of an α chain containing the Vα2 region paired with 
a β chain that contains the Vβ8.1 region.  The P14 transgenic TCR was shown to 
have higher affinity than the HY TCR. Indeed, P14 transgenic T cells express higher 
levels of CD5 and show a more efficient positive selection compared to the HY 
transgenic mice (7).  
1.3.1.3. OT-I transgenic mouse model 
OT-I TCR transgenic mice were first generated in 1994 (39). The OT-I transgenic 
TCR is specific for peptide SIINFEKL. This peptide derives from chicken ovalbumin 
and is presented in the context of MHC-I H2-Kb.  Accordingly, transgenic CD8+ T cells 
are positively selected on the H-2b background. The OT-I transgenic TCR consists of 
TCR chains containing Vα2 and Vβ5 regions. As judged by CD5 expression, the OT-I 
TCR has a higher affinity than P14 and HY TCRs (6, 48).  
1.3.2. MHC-II restricted transgenic mouse models  
1.3.2.1. OT-II transgenic mouse model 
OT-II transgenic mice were described in 1998 (8). The transgenic TCR expressed in 
these mice is specific for the chicken ovalbumin peptide epitop aa 323-329 
(ISQAVHAAHAEINEAGR) that is presented in the context of MHC I-Ab. Thus, the 
selection process in OT-II transgenic mice generates CD4+ T cells. The OT-II 
transgenic TCR contains the Vα2 and the Vβ5 regions. The OT-II transgenic TCR 
mediates an efficient positive selection of CD4+ T cells. 
1.4. Main T-cell populations 
1.4.1. αβ and γδ T cells  
T lymphocytes can be divided into two distinct groups. The first expresses the γδTCR 
and the second possesses the conventional αβTCR. T cells expressing the γδTCR 
represent a distinct population of T lymphocytes. Both in human and mouse, 
maturation of γδ T cells bifurcates from conventional αβ T cells at the DN2-DN3 
stage where the recombination of the γδ loci starts. (9, 57). How  T cells recognise 
antigens is not entirely clear. However, compelling evidences suggest that it is 
fundamentally different form αβ T cells. In fact, the antigen recognition process of the 
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γδTCR is independent from classical MHC molecules and does not require antigen 
processing. Moreover, it has been shown that γδ T cells recognise lipid antigens 
presented by the nonclassical MHC-I molecule CD1 (23, 33). Conversely, T cells 
expressing the αβTCR are restricted either to MHC-II or to MHC-I molecules and 
possess either the CD4 or the CD8 coreceptors, respectively. Within αβ T cells, CD8+ 
cells are mainly cytotoxic, whereas CD4+ lymphocytes function as helper or 
regulatory cells. CD4+ T cells control various aspects of the immune function such as 
the activity of CD8+ T cells, antibody production, and also antigen presentation by 
APCs. Thus, CD4+ T cells are indispensable for the organisation as well as for the 
coordination of the immune response (1, 46). 
1.5. T-cell signalling  
1.5.1. Structure of the αβTCR complex 
The αβTCR is expressed on the surface of all αβ T cells. The TCRβ and the TCRα 
heterodimer define the antigen-binding groove of the TCR. However, the TCR α and 
β chains are unable to generate signals. This function is performed by the TCR-
associated CD3 chains. The CD3 complex consists of five invariant polypeptide 
chains γ, δ, ε, δ, and ή, all of which possess signal transduction abilities. These 
chains associate and might form the following heterodimers: (δ δ), (δή), (δε), (γε). The 
(δδ) form is favoured since about 90% of the surface TCR complexes have (δδ) 
whereas only 10% of TCRs contain the (δή) heterodimer. The link between the 
different TCR and CD3 subunits is mainly based on ionic bridge interactions. In fact, 
the αβTCR heterodimer possesses positively charged amino acid residues in the 
transmembrane region that interact with the negative charged amino acid residues of 
δ subunits as well as with other CD3 components. Upon TCR engagement with its 
cognate ligand, numerous intracellular pathways are activated that at the end 
culminate in a functional outcome such as proliferation and differentiation. Proximal 
TCR signalling events are mediated exclusively via ITAMs (immunoreceptor tyrosine-
based activation motif) that are localised within the CD3 chains. CD3 γ, δ, and ε 
possess one ITAM whereas both δ and ή chains have three ITAMs. Thus, the whole 
TCR/CD3 complex contains in total 10 ITAMs. The molecular distribution of these 
motifs is represented in Figure 3. 
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1.5.2. Proximal signalling events in T cells  
A typical ITAM structure has the following aa sequence: YxxL/I/V x6-8 YxxL/I/V where 
x stands for any amino acid. The initiation steps of TCR signalling are dependent on 
the activity of the Src-family kinases. Upon TCR engagement with its ligand, the 
members of the Src-family kinases Lck and Fyn phosphorylate tyrosine residues 
within ITAMs. Thus, phosphorylated ITAMs are essential in mediating signalling 
events generated via the TCR (42, 46). Once the ITAMs become phosphorylated, 
they serve as docking sites for Zap70 (zeta associated protein of 70 kDa) a Syk 
kinase family member.  Zap70 is recruited to the phosphorylated ITAMs of CD3 δδ 
homodimer via its tandem SH2 domains. Upon binding to ITAMs, Zap70 localises to 
the proximity of Src kinases such as Lck and Fyn and in turn becomes 
phosphorylated and thereby activated. The most well-known downstream target of 
Zap70 is LAT (linker for activation of T cells). LAT plays a crucial role in T-cell 
development and activation. The cloning and characterisation of LAT was reported in 
1988 (125-128). Once phosphorylated on tyrosine residues, LAT recruits cytoplasmic 
molecules such as Grb2, Gads, PLC-γ.  In addition, LAT indirectly associates with 
several other proteins such as SLP76, Itk, Vav, Rho/Rac and Sos.  All these 
molecules are involved in the formation of a critical signalling complex that links the 
TCR to more downstream signalling events such as MAPK activation or Ca2+ flux 
(summarized in Figure 3) (56, 125-128). 
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Figure 3. Proximal TCR-mediated signalling events 
A typical structure of TCR complex is depicted according to the most frequent 
arrangement of the CD3 chains.  Disulfide bindings between the αβTCR, and ζζ 
dimers are depicted with black lines. ITAMs are represented as orange boxes. 
Phosphorylated ITAMs are indicated with red spots. Molecules involved in proximal 
signalling events are shown. Empty arrows represent signalling pathways whereas 
black arrows indicate activation.  
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1.5.3. Transmembrane adaptor proteins (TRAPs) 
The discovery of TRAPs  was a major achievement in the history of T-cell signalling. 
All TRAPs possess a short extracellular domain and a long cytoplasmic part. Per 
definition, TRAPs possess neither enzymatic nor transcriptional activity. All TRAPs 
contain multiple tyrosine-based signalling motifs (TBSMs) (Figure 4). Upon 
phosphorylation, TRAPs recruit signalling molecules via TBSMs thereby they 
organize multiprotein signalling complexes at the plasma membrane. Thus, TRAPs 
are essential to link membrane receptors to more downstream signalling events. To 
date, the following TRAPs have been identified: LAT, PAG, NTAL, LIME, that are 
localised to the GEM fractions and LAX, TRIM, and SIT which are positioned outside 
of GEMs.  
 
Figure 4. Transmembrane adaptor proteins (TRAPs) 
Overall structure of the known TRAPs. The plasma membrane is depicted with either 
empty or blue boxes indicating non-GEM or GEM membrane compartments, 
respectively. Tyrosine-based signalling motifs within each adaptor protein are 
depicted as orange boxes. Other motifs such as proline rich motifs are indicated by 
circles. The amino acid sequences of TBSMs are shown adjacent to the 
corresponding motifs. 
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1.5.4. The SH2-domain-containing protein tyrosine phosphatase (SHP2)-
interacting transmembrane adaptor protein (SIT) 
1.5.4.1. Structure of SIT 
The transmembrane adaptor protein SIT was identified in 1999 (63, 85). SIT is a 30-
40kDa disulfide-linked homodimeric polypeptide with a very short extracellular 
domain (18aa) that contains a single N-glucosylation motif (N26) and one cysteine 
residue C27, which is involved in the formation of an interchain disulfide bound. The 
extracellular domain of the protein is followed by a 19aa long intramembrane 
segment (aa 41-60) as well as by a long cytoplasmic domain (aa 61-196). Although 
the overall structure of SIT is similar to those of other TRAPs, SIT has a unique 
feature. In fact, it is the only TRAP possessing an extracellular glycosylation 
accounting for 20 kDa of its molecular weight. The intracellular domain of SIT 
contains five TBSMs among which one motif is a conventional ITIM. They are as 
follows: Y90GNL, Y128TSL, VKY148SEV, Y168ASV, Y188ANS.  These motifs represent 
potential sites for tyrosine phosphorylation. Upon TCR triggering in both HPB-ALL 
and Jurkat T cells, SIT becomes phosphorylated. The overall level of tyrosine 
phosphorylations among TBSMs is summarised as follows: 
YGNL≥YASV>YTSL>ITIM>YANS (63, 85). In addition, both Northern and Western 
blot analysis revealed that SIT is mainly expressed in lymphoid organs such as the 
thymus, lymph node and spleen (63, 85, 103). 
1.5.4.2. Function of SIT 
In Jurkat T cells, SIT was shown to negatively regulate TCR-mediated NF-AT 
activation. Although it has been shown that, upon TCR engagement, SIT recruits 
SHP2 via its ITIM, the negative regulatory effect of SIT on TCR-mediated signalling 
appears to be exclusively mediated via the YASV motif.  Additionally, it also has been 
shown that upon TCR triggering Grb2 binds to SIT via the YGNL-and the YANS- 
motifs.  However, the YGNL motif represents the major Grb2 binding site. The ability 
of SIT to bind molecules that are important in both positive and negative regulation of 
TCR-mediated signalling raises the possibility that SIT might have a dual function. 
Indeed, in the absence of the YASV motif SIT lost its negative regulatory effect on 
NF-AT activation and instead showed a positive regulatory function mediated via the 
YGNL motif. Further characterisation revealed that in pervanadate stimulated Jurkat 
T cells SIT interacts with Csk, a potent negative regulator of the Src family kinases, 
via the YASV motif. Thus, it is most likely Csk the main candidate to mediate the 
negative regulatory effect of SIT in Jurkat T cells. In summary, upon TCR stimulation 
SIT becomes phosphorylated and subsequently recruits SHP2 via its ITIM, Grb2 
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mainly via its YGNL and Csk via the YASV motif (63, 85). However, the functional 
relevance of these interactions especially in primary T cells is not yet clear. 
1.6. Negative regulation of TCR signalling 
1.6.1. Immunoreceptor tyrosine-based inhibitory motifs 
The consensus sequence of a typical immunoreceptor tyrosine-based inhibitory motif 
(ITIM) is S/I/V/LxYxxI/V/L where x stands for any amino acid. ITIMs play an important 
role in the negative regulation of TCR-mediated signalling by recruiting inhibitory 
molecules possessing SH2 domains. These molecules are tyrosine and lipid 
phosphatases such as SHP-1, SHP-2, and SHIP respectively. 
1.6.2. SHP-2 (SH2 domain containing protein tyrosine phosphatase) as 
negative regulator of immunoreceptor signalling 
The tyrosine phosphatase SHP-2 is expressed ubiquitously (74). The inhibitory role 
of SHP-2 in T cells is not entirely clear. The recruitment of SHP-2 to inhibitory 
receptors is mediated via its tandem SH2 domains that bind to conventional ITIMs. 
Primary studies have shown that SHP-2 acts as a positive regulator of Ras/ERK 
pathway downstream of growth factor receptors. In this regard, SHP-2 might 
counterbalance the function of Csk. However, accumulating evidences suggest that 
SHP-2 might exert a negative regulatory role in T cells. Data obtained from mice in 
which the SHP-2 binding site of the common gamma chain receptor (gp130) of IL-6 
was mutated suggest a potent negative regulatory role of SHP-2 on cytokine 
mediated signalling. It seems that SHP-2 dephoshorylates STAT proteins. These 
mice also developed autoimmunity as well as spleenomegaly further indicating the 
negative regulatory role of SHP-2 (55, 79, 95).  In addition, macrophages that lack 
SHP-2 display an elevated FcγR-and TLR-mediated IFN production (95). Finally, 
SHP-2 was shown to associate with CTLA-4 (55). Authors have suggested the 
presence of an inhibitory complex consisting of SHP-2, CTLA-4, and TCRδ that 
results in dephosphorylation of the TCRδ chain either directly or indirectly by 
dephosphorylating Lck, thus resulting in dampening of proximal signalling events 
(55). Compelling evidences suggest that SHP2 might also inhibit TCR-mediated 
signalling via the docking protein Gab2 (122, 123). Moreover, the recently described 
inhibitory molecule BTLA (B and T lymphocyte attenuator) that is upregulated upon T 
cell activation was shown to recruit SHP-1 and SHP-2. BTLA deficient mice are 
sensitive to the induction of autoimmune disease. Moreover, T cells from these mice 
are hyperreactive to CD3 mediated stimuli in vitro, further indicating the potential 
negative regulatory role of SHP-2 in immunoreceptor signalling (120). 
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1.6.3. The role of Csk as a negative regulator of Src kinases 
Csk (C-terminal Src kinase) is a 50 kDa protein tyrosine kinase that is ubiquitously 
expressed (19, 54, 70). However, its expression is more pronounced in hematopoetic 
cells. The overall structure of Csk resembles that of Src kinases. It possesses a C-
terminal SH3 domain, an SH2 domain, as well as a catalytic domain. Csk is able to 
inhibit Src kinases by phosphorylating the C-terminal inhibitory tyrosine residue (70). 
Unfortunately, a more detailed analysis of Csk function is not possible since mice 
deficient for Csk die at embryonic day 9-10 (43, 71).  To circumvent this problem Csk 
conditional knockout mice were generated.  An interesting finding was that immature 
thymocytes in these mice were able to mature from the DP to the SP CD4+ stage. Of 
note, development of CD4+ T cells in the absence of Csk was MHC-II independent 
(97). Thus, constitutive  activation of Src kinases abrogates the need for proper pre-
TCR signalling and MHC restriction in developing CD4 T cells. Moreover, Csk 
overexpression studies in a T-cell line (BI-141) revealed a profound inhibition of 
global tyrosine phosphorylation and IL-2 production upon TCR stimulation. These 
findings indicate that Csk-mediated regulation of Src kinases is essential during T-
cell development and peripheral T-cell function (18). Csk constitutively associates 
with the PEST domain-enriched tyrosine phosphatase (PEP) that is expressed only 
in haematopoietic lineages (21). In T-cell lines, PEP overexpression was shown to 
inhibit TCR mediated signalling. (22) Thus, Csk might also exert its negative 
regulatory function via PEP. Taken together, Csk negatively regulates the activation 
status of Src kinases and thus, has a strong impact on both T-cell development and 
function. 
1.6.4. CD5 is a negative regulator of TCR-mediated signalling 
The CD5 molecule belongs to the scavenger receptor cysteine rich B (SRCR) family.  
The extracellular part of CD5 contains three SRCR domains followed by a 
hydrophobic transmembrane region and a relatively long intracellular domain. The 
human CD5 molecule was cloned in 1986 whereas the mouse CD5 was cloned in 
1987. The intracellular part of CD5 contains four tyrosine residues among which two 
are functionally important. Tyr441 is  located within an imperfect ITAM motif whereas 
Tyr378 is a part of an ITIM-like motif. CD5 was shown to become tyrosine 
phosphorylated upon TCR triggering most likely by Lck (88). Once phosphorylated, 
CD5 recruits PI3K (p85)  via its ITAM-like motif and SHP-1 via its ITIM-like motif  (15, 
25, 27, 88).  Additionally, it has been shown that CD5 colocalises with the TCR 
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complex (81). Thymocytes from CD5-/- mice are hyperreactive and show an 
enhanced proliferation and Ca2+ mobilisation upon TCR triggering in vitro. The 
lowered threshold of activation leads to an altered T-cell development in these mice.  
When crossed onto HY or P14 transgenic background CD5-/- mice showed a more 
activated phenotype as well as an enhanced positive selection (6, 114). In addition, 
signalling molecules that are essential for proper T-cell activation such as LAT and 
Vav were shown to be hyperphosphorylated in CD5 deficient thymocytes. Taken 
together, these data suggest that CD5 acts as a potent negative regulator of TCR 
mediated signalling by recruiting SHP-1 to the plasma membrane via its ITIM-like 
motif (83). Thus, CD5 might contribute in a negative feedback loop that 
counterbalances TCR-mediated signalling. This view is further supported by the fact 
that the surface expression of CD5 on T cells is proportional to the affinity of the TCR 
(6, 7). 
1.7. T-cell homeostasis 
1.7.1. The role of different factors in T-cell homeostasis 
The number of peripheral T cells is tightly regulated during the course of life. The 
mechanism that is responsible for maintaining peripheral T-cell numbers relatively 
constant is termed as T-cell homeostasis. Various mechanisms contribute to regulate 
the size of the peripheral T-cell pool.  In young mice, the thymus plays a major role in 
T-cell pool maintenance by generating naïve T cells. However, survival and self-
renewal of naïve T cells contribute to maintain constant T-cell numbers during 
adulthood. Peripheral T cells require continuous signals to survive. These survival 
signals are both TCR and cytokine mediated. T cells deprived of such signals die 
rapidly. An experimental model to investigate T-cell homeostasis (survival and self 
renewal capacity) is the adoptive transfer of small numbers of T cells into 
lymphopenic recipients. Under lymphopenic conditions, adoptively transferred T cells 
undergo rapid proliferation to repopulate the “empty niche”. Natural lymphopenia 
driven T-cell proliferation occurs after chemotherapy, or in AIDS patients, as well as 
patients suffering from other diseases causing severe immunodeficiency (29, 36, 61).  
In addition, a partial lymphopenic situation occurs during early ontogenesis.  For 
instance, newborn mice possess only few T cells in the periphery. Thus, they are 
considered to be partially lymphopenic.  
Experimental mouse models of lymphopenia are sublethaly irradiatiated mice or 
rag1/rag2 deficient mice. An additional way to induce lymphopenia is injecting T-cell 
depleting antibodies (78). The capability of adoptively transferred T cells to expand in 
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a lymphopenic host is a measure of the homeostatic „fitness” or self-renewal capacity 
of the donor cells (47).  
1.7.2. Homeostatic proliferation of T cells  
The factors that mediate T-cell survival and homeostasis are not entirely clear. 
Accumulating evidences suggest that both CD4+ and CD8+ naïve T cells require 
continuous low affinity TCR:self-peptide-MHC induced signals to survive upon 
adoptive transfer  (13, 30, 35, 47, 64, 69, 77, 100, 111, 113).  In line with these 
observations low affinity peptides that mediate positive selection in the thymus have 
been shown to be involved in regulating peripheral T-cell survival and homeostasis of 
both MHC-I and MHC-II restricted T cells (30, 35). Studies performed on TCR 
transgenic mouse models have revealed that “homeostatic fitness” of T cells 
correlates with the avidity of the TCR (47, 48). T cells that express  TCR with higher 
avidity have proliferative advantage over the cells possessing TCR with lower avidity 
when adoptively transferred into lymphopenic hosts (30, 48, 108). Indeed, adoptively 
transferred T cells from TCR transgenic mice carrying TCRs with different affinities 
display different capability to proliferate under lymphopenic conditions  (13, 30, 35, 
47, 64, 69, 77, 93, 111, 113) . In line with these observation transgenic CD8+ T cells 
carrying the low affinity HY TCR are unable to undergo homeostatic proliferation in 
lymphopenic hosts (30, 77, 113). The fact that T-cell proliferation and survival 
capacity in lymphopenic hosts are proportional with TCR affinity, indicates that the 
strength of TCR-mediated signal is crucial in setting the homeostatic capability of T 
cells. 
1.7.3. The role of cytokines in T-cell survival and homeostasis 
In addition to proper TCR:self-peptide-MHC interaction cytokines, especially IL-7 and 
IL-15 are also essential in mediating T-cell survival and homeostasis. Studies utilizing 
IL-7Rα deficient mice have shown that signalling via IL7Rα is essential for 
homeostatic proliferation of naïve T cells in lymphopenic hosts (38, 98, 99). In line 
with this finding, knockout mice lacking either IL-7Rα or IL-7 display a severe 
lymphoid hypoplasia, thus demonstrating the potent role of IL-7 in T-cell homeostasis 
and survival. Treatment of thymectomized mice with IL-7 blocking antibodies leads to 
a reduction of Bcl-2 levels in T cells thus, results in shortening the half-life of 
peripheral T cells (58, 90, 96, 118). However, the contribution of cytokines to T cell 
homeostasis might also depend on the degree of lymphopenia. Under extreme 
lymphopenic conditions IL-7R mediated signals  seem to play a primary role whereas 
under less severe lymphopenia TCR:self-peptide-MHC mediated signals are 
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essential to induce lymphopenia induced expansion of T cells (99).  In contrast to 
naïve T cells, survival and homeostasis of memory T cells is less dependent on TCR: 
self-peptide-MHC interaction but rather requires cytokines (47, 69, 109). The main 
cytokine that triggers survival and proliferation of memory CD8+ T cells is IL-15 (58, 
129). CD8+ memory T cells are able to survive if IL-15 is present even in the absence 
of TCR-derived signals (69). On the contrary, IL-15 seems to be dispensable in 
memory CD4+ T-cell survival and homeostasis indicating that homeostasis of 
memory CD4 and CD8 T cells is likely differentially regulated (112). In conclusion, 
survival and homeostasis of both CD4+ and CD8+ T cells require TCR:self-peptide-
MHC mediated signals yet, the relative contribution to the homeostatic response by 
TCR and cytokine signals critically depends on both the degree of lymphopenia and 
phenotypic characteristics of individual T cells.   
1.7.4. Phenotype of T cells undergoing lymphopenia-induced expansion 
T cells undergoing homeostatic expansion stepwise acquire a memory-like 
phenotype as they upregulate some memory markers such as CD44, CD122 (IL-2/IL-
15Rβ) (17, 32, 37, 45, 68). However, they keep the expression of the naive T-cell 
marker, CD62L. Moreover, T cells undergoing lymphopenia-induced proliferation do 
not become fully activated and do not upregulate activation markers such as CD69 or 
CD25. Finally, functional assays revealed that TCR-mediated response (IFNγ, IL-2 
production, proliferation) of these cells partially resembles those of memory cells 
though with less amplitude. Thus, T cells undergoing homeostatic proliferation show 
a bimodal profile that resembles to that of both memory and naïve T cells (17, 45, 68, 
80).  
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2. Results  
2.1. Genotyping SIT deficient mice 
SIT-deficient mice were generated in close cooperation with Dr. Klaus Pfeffer using a 
sit gene targeting construct designed by Dr. Eddy Bryns (Figure 5A). Briefly, the sit 
gene was disrupted by a standard gene targeting strategy. The entire coding 
sequence of SIT was replaced by a neomycin resistance cassette. Targeted mutation 
and Mendelian segregation was further assessed by genotyping SIT-deficient mice 
by standard PCR using genomic DNA purified from mouse-tail tissue. Figure 5B 
shows PCR products typically obtained from wild-type, heterozygote, and SIT 
knockout mice. The PCR product of the wild-type allele is 300 base pair long while 
the product of the muated allele is 500 base pair long.  As expected, PCR products 
obtained from heterozygote mice show two distinct bands corresponding to the PCR 
products obtained from both wild-type and mutant alleles, respectively. 
 
Figure 5. SIT gene targeting and genotyping strategies 
A) Partial restriction map of the SIT locus and the targeting cassette. Filled boxes 
indicate exons. Restriction sites are indicated as follows: N (NotI), B (BamHI), M 
(MluI) P (PstI), X (XbaI). Abbreviations: NEO: neomycin, TK: thymidine kinase. B) 
Genomic DNA was purified from wild-type, heterozygote or SIT-deficient mice from 
tail tissue. Subsequently a standard PCR reaction was carried out. PCR products 
were typically loaded onto 2% agarose gel. PCR products are shown from SIT+/+, 
SIT+/- and SIT-/- mice, respectively. Corresponding marker lanes are indicated on the 
left side. 
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2.2. Expression of SIT in mice 
2.2.1. SIT is expressed predominantly in T cells 
Previous analysis of different mouse tissues revealed that SIT is expressed mainly in 
primary and secondary lymphoid organs (63, 103). In order to further determine the 
expression of SIT in mouse primary cells, lysates were prepared from lymphoid 
organs and SIT expression was subsequently determined by standard western blot. 
In agreement with previous results, SIT is abundantly expressed in the thymus but 
less in the spleen (Figure 6). Moreover, among primary cells, SIT is strongly 
expressed in CD3+ T cells but it is hardly detectable in B220+ B cells. Thus, SIT is 
mainly expressed in both immature and mature T cells. 
 
 
 
 
 
 
 
 
Figure 6. SIT is mainly expressed in T cells  
SIT expression in primary mouse cells. Thymocytes (lane 1) total spleen cells (lane 
2), purified T cells (lane 3) and purified B cells (lane 4) were isolated from wild-type 
mice, lysed and subsequently an SDS PAGE was carried out. Membrane was probed 
with anti-SIT antibody. Equal protein loading is shown by reprobing the membrane 
with an anti-ERK antibody. 
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 2.3. The role of SIT in T-cell development 
2.3.1. SIT-/- mice show normal B-cell, but altered T-cell development 
SIT deficient mice were born at the expected Mendelian frequency, they were viable, 
fertile, and showed no signs of abnormalities. Flow cytometry analysis revealed 
alteration neither in B-cell development nor in the distribution of B-cell subsets in the 
bone marrow, spleen or lymph nodes (Figure 7A and (103)). However, FACS 
analysis revealed that SIT-deficient mice had an altered T-cell development. Figure 
7B shows that there is a marked reduction in both percentages and absolute 
numbers of both CD8+ and CD4+ SP thymocytes (see also (103)). Conversely, I 
observed an increased proportion of DP thymocytes in SIT-/- mice. In agreement with 
these observations, a significant decrease of thymocytes expressing high levels of 
TCR (as a sign of terminal maturation) was found in SIT-/- animals (Figure 7B). 
Nonetheless, the early stages of thymic development were found to be normal in  
SIT-/- mice  (Figure 7C). These results indicate that SIT is dispensable during the 
early steps of thymic development but it is required during the transition from the DP 
to the SP stage.  
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Figure 7. Normal B-cell but altered T-cell development in SIT-/- mice  
A) Bone marrow cells were isolated from both wild-type and SIT-deficient mice and 
subsequently analysed by flow cytometry for the expression of IgM, B220, and CD43. 
B) Thymocytes from SIT+/+ and SIT-/- mice were isolated and single cell suspensions 
were stained for CD4, CD8, and βTCR. C) Early T-cell development. Thymocytes 
from wild-type and SIT-knockout mice were isolated and subsequently stained for 
CD44 and CD25. Numbers indicate percentages of cells within each quadrants or 
region. All FACS profiles shown here are representative of multiple experiments. 
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2.3.2. SIT- deficient thymocytes show an activated phenotype 
To shed further light onto the alteration of thymic development in SIT-/- mice, I 
analysed the expression levels of surface markers whose expression is differentially 
regulated during thymic development. First, I investigated CD5 the expression of 
which directly correlates with the intensity of pre-TCR and TCR-mediated signalling 
(6, 7). Flow cytometric analysis revealed that SIT-/- mice display an elevated 
expression of CD5 on total as well as on DP thymocytes. Next, I studied the 
expression of the activation marker CD69, which has been shown to be differentially 
regulated during T-cell development (5). Similar to CD5, CD69 expression was also 
found to be upregulated in both total and DP thymocytes from SIT-/- mice (Figure 8). 
These results indicate that SIT-/- thymocytes receive a stronger signal via the TCR 
and in turn display a more activated phenotype. Thus, loss of SIT results in a lowered 
threshold of TCR-mediated activation in thymocytes. 
 
 
 
 
 
 
 
 
 
 
Figure 8. SIT-/- thymocytes show a more activated phenotype 
Representative histogram overlays of CD5 and CD69 expression on DP or total 
thymocytes derived from wild-type (shaded histograms) or SIT-deficient (empty 
hitograms) mice. Single cell suspensions of thymocytes were prepared and stained 
with CD4, CD8, CD69 and CD5 antibodies.  
Total DP 
 CD5 
   CD69 
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2.3.3. Enhanced positive selection in MHC-I restricted transgenic mice 
In order to study the role of SIT in positive and negative selection, I took the 
advantage of TCR transgenic mice. Usage of TCR transgenic mice is reported to be 
suitable to study thymic selection processes (6, 20, 50). First, I used the HY 
transgenic mouse system that enabled us to analyse of both positive and negative 
selection. The HY transgenic TCR is thought to have low affinity to its selecting 
ligand (28). Thus, we hypothesised that in the absence of SIT the signalling of the HY 
specific TCR would become stronger. This would result in a more efficient positive 
selection. To test this hypothesis, I characterised T-cell development of HY TCR 
transgenic SIT-deficient mice. 
Flow cytometric analysis showed that the expression of CD5 was elevated on both 
DP and positively selected CD8+ SP cells from SIT-/- HY tg female mice (Figure 9A 
right panel). This observation indicates that indeed thymocytes receive a stronger 
signal via TCR in these mice. To directly demonstrate that SIT regulates TCR 
signalling threshold, I investigated the activation of ERK, a downstream effector 
molecule induced upon TCR triggering. Figure 9A shows that the level of 
phosphorylated ERK was higher in DP thymocytes from SIT-deficient HY transgenic 
mice compared to wild-type HY transgenic animals (MFI 59.0 vs. 30.4). Remarkably, 
the level of phosphorylated ERK was similar after in vitro stimulation with PMA (MFI 
170 vs. MFI 183), ruling out the possibility that cells express different amounts of 
phosphorylable ERK or display an  overall decreased ability to phosphorylate ERK 
(Figure 9A and (103)). Thus, as expected SIT deficiency resulted in a stronger 
signalling via the TCR.  
In addition, an interesting observation was that the proportion of non-transgenic CD4+ 
T cells was strongly reduced in SIT-/- HY transgenic mice. Normally, this population 
arises after a pairing of the transgenic TCRβ chain with non-transgenic TCRα chains.  
However, in SIT-deficient HY transgenic mice the enhanced HY TCR-mediated 
signalling resulted in a more efficient suppression of further rearrangement of the 
TCRα locus. This resulted in a reduced proportion of non-transgenic CD4+ T cells 
(Figure 9B lower panel).    
Taken together, the elevated expression of CD5, the more mature phenotype, a more 
activated ERK, and a more effective suppression of the recombination of non-
transgenic TCRα locus clearly indicate that loss of SIT resulted in an enhanced 
positive selection in the HY transgenic mouse model.   
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Figure 9. Enhanced positive selection in SIT-/- HY transgenic mice 
A) Thymocytes from HY TCR tg SIT+/+ (shaded) or from HY TCR tg SIT-/- mice 
(empty) were isolated, fixed, permeabilized and stained intracellulary to determine 
the level of phosphorylated ERK. Corresponding staining with isotype control 
antibody is indicated with a dotted line. Expression levels of CD5 and HSA on gated 
DP or CD8 SP thymocytes (right upper and lower panels). B) Upper panel: lymph 
node cells from SIT+/+ and SIT-/- HY transgenic mice were isolated and stained with 
the T3.70 antibody, recognizing the clonotypic transgenic TCRα chain and with F3.21 
antibody recognizing the transgenic TCRβ chain, respectively. Lower panel: 
expression of CD4 and CD8 on lymph node cells of HY transgenic SIT+/+ and SIT-/- 
mice. Numbers indicate percentages in each quadrant. 
 
 
To further test the consequences of a more efficient TCR-mediated signalling on 
thymocyte differentiation I also studied the level of HSA (CD24), a marker  whose 
expression inversely correlates with the maturation status of thymocytes. As 
expected, flow cytometric analysis revealed that SIT-/- HY transgenic thymocytes 
expressed strikingly less HSA indicating that they displayed a more mature 
phenotype (Figure 9A lower panel). 
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2.3.4. SIT deficiency resulted in a conversion from positive to negative 
selection in TCR transgenic mice  
Based on the model (depicted in  Figure 2) we expected that loss of SIT would result 
in a shift from positive to negative selection. Indeed, I observed a reduction in the 
total number of HY TCR transgenic DP thymocytes in SIT-deficient mice (Figure 
10A). Thus, loss of SIT not only resulted in enhanced positive selection but also 
induced a partial conversion from positive to negative selection.  
Similar to HY transgenic mice, SIT deficient P14 mice also showed a marked 
reduction in the number of DP thymocytes  and displayed an even more dramatically 
reduced thymic cellularity (Figure 10B). Thus, loss of SIT resulted in a shift from 
positive to negative selection also in P14 transgenic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Conversion from positive to negative selection in HY and P14 TCR tg 
SIT-/- mice 
Single cell suspensions were prepared from HY (A) and P14 (B) transgenic SIT+/+ 
and SIT-/- mice and subsequently stained for CD4, CD8, and the transgenic TCR 
expression. Expression profile of CD4 and CD8 on gated transgenic thymocytes is 
shown. Numbers indicate percentages in each quadrant. Bar graphs show cellularity 
(x106) of each thymocyte subset. Black bars represent wild-type, whereas empty bars 
indicate SIT-deficient transgenic mice. 
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Finally, I studied the effect of the loss of SIT on the development of OT-I TCR 
transgenic T cells,  which express a TCR with strong affinity. Surprisingly, I found no 
alteration of thymic development in SIT-/-OT-I transgenic mice (Figure 11 right panel). 
In addition, I also wished to investigate whether SIT has an effect on the 
development of CD4+ T cells. To this end, I investigated thymic development in MHC-
II restricted OT-II transgenic mice. However, I did not find any alteration of T-cell 
development in these mice (Figure 11 left panel). Therefore, we hypothesised that 
SIT influences the development of CD8+ T cells that carry TCR with low or 
intermediate affinity (see also Figure 13). 
 
Figure 11. SIT is dispensable for the development of OT-I and OT-II transgenic 
T cells  
Single cell suspensions of thymocytes from SIT+/+ and SIT-/- OT-II and OT-I 
transgenic mice were prepared and stained for CD4, CD8, and transgenic (Vα2) TCR 
expression. Numbers indicate percentages of cells in each quadrant. 
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2.3.5. Normal negative selection in the absence of SIT 
In order to find out whether SIT plays a role in  negative selection, I also investigated 
SIT-deficient and wild-type TCR transgenic HY male mice.  As indicated in figure 12, 
I could not find any obvious differences between thymocytes from SIT+/+ and SIT-/- HY 
transgenic male mice. This result indicates that loss of SIT does not have a direct 
effect on negative selection at least in the HY transgenic mouse model (103).  
 
Figure 12. Normal negative selection in HY male TCR transgenic SIT-/- mice 
Thymocytes were isolated from either wild-type or SIT-deficient male HY transgenic 
mice. Subsequently cells were stained with CD4 ,CD8, and T3.70 antibodies and 
analysed by flow cytometry. Representative profiles showing CD4 and CD8 
expression of gated transgenic T3.70+ thymocytes are shown. 
 
 
Figure 13. Effect of SIT on T-cell development 
Increasing colour intensity indicates increasing TCR affinities. Selection outcomes of 
MHC-I restricted SIT-deficient and wild-type TCR transgenic thymocytes are 
indicated. Empty arrows represent the shift of TCR affinity caused by the loss of SIT. 
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2.4. Altered distribution of peripheral T-cell subsets in SIT-/- mice 
2.4.1. Reduced peripheral T-cell numbers in SIT-deficient mice 
In order to investigate whether SIT deficiency also resulted in an alteration of the 
distribution of peripheral T-cell pools,  first I investigated the cellularity of peripheral 
lymphoid organs from SIT-deficient mice. As figure 14 shows, SIT deficiency resulted 
in a reduction of peripheral CD8+ T-cell number in both spleen and lymph nodes, 
whereas CD4+ T cells were only slightly affected. (see also (103)).  
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Figure 14. Altered T-cell subsets in SIT-deficient mice 
Numbers of CD4+ and CD8+ T cells in lymph nodes and spleen from wild-type and 
SIT-deficient mice. Lymph node and spleen cell suspensions were prepared form 3 
weeks old wild-type and SIT-deficient mice and stained for CD4 and CD8 expression. 
Based on FACS analysis, absolute numbers of CD4 and CD8 T cells were 
calculated. 
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2.4.2. SIT-deficiency resulted in alteration of naïve CD8+ T cells 
The peripheral T-cell pool consists of naive and memory subpopulations that express 
low and high levels of CD44, respectively.  To find out which T-cell subset was 
affected by the loss of SIT, I performed a detailed characterisation of both naïve and 
memory CD4+ and CD8+  cells. Figure 15 indicates that the number of CD44lowCD8+ 
naïve T cells was strongly reduced both in the spleen and lymph nodes of SIT-
deficient mice (Figure 15, left panel). On the contrary, naïve CD4+ T cells were not 
significantly altered by the loss of SIT (Figure 15 right panel). 
 
 
 
 
 
Figure 15. Decreased number of naïve CD8+CD44low cells in SIT-/- mice 
Absolute numbers of CD8+CD44low and CD4+CD44low T cells in lymph node and 
spleen. Based on CD44 expression absolute numbers of CD4+ and CD8+ CD44low T 
cells were calculated. Mean±Standard Error of the Mean values (SEM) are shown in 
each graph. Empty triangles indicate SIT-knockout whereas filled squares represent 
wild-type mice. 
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As our data suggested that, the loss of SIT more strongly affected CD8+ T cells, I 
further investigated T-cell homeostasis in SIT-/- mice.  In young mice, thymic output is 
essential to keep naive T-cell numbers constant in the periphery. I showed previously 
that the generation of SP thymocytes was reduced in SIT-/- mice (Figure 7). The 
reduced generation of T-cell precursors in the thymus appeared to correlate with the 
reduced number of naïve T cells in SIT-deficient mice. Recent thymic emigrants 
(RTEs) are defined as T cells with direct thymic origin. They can be identified by the 
expression of CD103 (αE integrin) (65, 106). Therefore, I analysed whether RTEs are 
affected in SIT-deficient mice. As expected, SIT-/- mice displayed a marked reduction 
in the percentage of RTEs (CD44lowCD103+) indicating that the loss of naïve CD8+ T 
cells is at least partially due to the reduced generation of T-cell precursors (Figure 
16). 
 
 
Figure 16. Reduced proportion of recent thymic emigrants in SIT-/- mice 
Representative CD44 and CD103 expression profiles of CD8+ gated spleen T cells. 
Single cell suspensions were prepared from spleen from both wild-type and SIT 
knockout mice and stained with CD8, CD44 and CD103 antibodies. Numbers 
indicate percentages in each quadrant. 
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2.4.3. The decreased number of CD8+ naive T cells in SIT-/- mice is not due to 
survival defect  
To further study whether an intrinsic T-cell survival defect might also contribute to the 
loss of naive CD8+ T cells in SIT-deficient mice, I tested the survival capacity of 
lymph node T cells in vitro. Total lymph node cells from SIT+/+ and SIT-/- mice were 
prepared and cultured in medium for three days. Percentages of living cells were 
assessed by FACS analysis. However, survival of SIT deficient and wild-type lymph 
node cells was comparable (Figure 17A). In agreement with these data, the 
antiapoptotic factor Bcl-2, whose expression is reported to directly correlate with T-
cell survival, was also equally expressed in SIT+/+ and SIT-/-CD8+ T cells (Figure 17B) 
(49, 53).  An additional mechanism that might also contribute to the loss of naive 
CD8+ T cells could be an increased apoptosis. To address this issue, I stained ex 
vivo isolated lymph node cells and spleenocytes with Annexin V. However, I found no 
differences between SIT-deficient and wild-type CD8+ T cells (Figure 17C). Taken 
together, these observations suggest that the loss of naïve CD8+ T cells observed in  
SIT-/- mice is not due to an intrinsic survival defect. 
 
Figure 17. Normal survival rate of SIT-/- CD8+ T cells 
A) Lymph node cells (LN) from SIT+/+ and SIT-/- mice were prepared and cultured for 
3 days in mouse medium and subsequently analysed by FACS. Bar graphs grey 
(wild-type) and empty (knockout) indicate percentage of gated living cells. B) 
Expression of Bcl-2 in SIT+/+ and SIT-/- lymph node cells. Cells were isolated from 
SIT+/+ (shaded) and SIT-/- (empty) mice and subsequently stained for CD4, CD8 and 
Bcl-2 expression. The bcl-2 expression profile of gated CD8+ T cells is shown. The 
dotted line indicates corresponding isotype staining control. C) CD8+ T-cell apoptosis. 
Ex vivo isolated lymph nodes and spleen cells were stained with CD8 antibody and 
subsequently with Annexin-V. Mean±Standard Error of the Mean values (SEM) are 
shown in each graph.  
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2.4.4. Comparable short-term steady-state proliferation between SIT+/+ and 
SIT-/- T cells 
A possible slower steady-state proliferation could also account for the decreased 
number of CD8+ T cells in SIT-deficient mice. In order to check this possibility, I 
performed BrdU incorporation assays. Mice were fed with 0.8mg/ml BrdU in their 
drinking water for 7 days. Then, single cell suspensions from both spleen and lymph 
nodes were prepared and stained for the expression of CD4, CD8 and BrdU 
incorporation. As depicted in figure 18, I found no differences in the rate of BrdU 
incorporation between SIT-/-CD8+ and SIT+/+CD8+ T cells, thus demonstrating that the  
short-term steady-state proliferation of CD8+ T cells is normal in SIT-/- mice. 
 
Figure 18. Normal steady-state proliferation of SIT-/- CD8+ T-cells 
Lymph node and spleen cells were harvested from BrdU treated (7 days) wild-type 
and SIT knockout mice and stained with CD4 and CD8 antibodies. Subsequently 
cells were fixed, permeabilized and further stained intracellulary with an anti-BrdU 
antibody. Representative BrdU incorporation profiles of CD8+-gated lymph node or 
spleen T cells are shown. Numbers indicate percentages of cells. 
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2.5. Altered T-cell homeostasis in SIT-deficient mice 
2.5.1. CD8+ peripheral T cells of SIT-/- mice are almost exclusively CD44hi 
Further investigations of peripheral lymphoid organs also revealed that SIT-deficient 
mice had a strongly increased proportion of CD8+CD44hi cells both in lymph nodes 
and spleen, whereas CD4+ T cells were much less affected (Figure 19). These data 
indicate that CD8+ T-cell homeostasis is altered in SIT-deficient mice, that results  in 
a bias of CD8+ T cells toward a memory-like phenotype. 
 
 
  
 
 
 
 
 
Figure 19. CD8+ T lymphocytes from SIT-/- mice consist mainly of CD44high cells  
Single cell suspensions of spleen and lymph nodes from SIT+/+ and SIT-/- mice were 
prepared and stained for the expression of CD4, CD8, and CD44. Here, the CD44 
expression profile of gated SIT-/- CD4+ and CD8+ T cells is shown. Numbers indicate 
percentages in each region. 
 
2.5.2. SIT-deficient CD8+CD44high cells show a bimodal surface profile 
Phenotypically, T cells undergoing homeostatic proliferation are memory-like cells 
with a bimodal profile, as they express markers of both naïve and memory cells. 
Based on my previous data loss of SIT seemed to result in an altered peripheral T-
cell homeostasis. To shed further light onto this phenomenon, I performed a more 
detailed FACS analysis of CD8+CD44high cells from both lymph node and spleen of 
SIT-/- mice. These studies revealed that SIT-deficient mice had an increased 
proportion of CD8+CD44highCD122highCD62Lhigh cells compared with wild-type 
counterparts (Figure 20A). In addition, both SIT+/+ and SIT-/- CD8+CD44high cells 
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expressed comparable low levels of the activation marker CD25 (IL-2Rα) (Figure 
20C). This profile (CD8+CD44highCD122highCD62Lhigh) observed in SIT-/- mice is 
identical to the profile of T cells undergoing homeostatic proliferation. This 
observation further indicates that CD8+CD44highCD122highCD62Lhigh SIT-/- T cells are 
not true antigen experienced memory but rather memory-like cells generated by an 
altered peripheral T-cell homeostasis.  
 
Figure 20. Bimodal  profile of SIT-/-CD44hiCD8+ T cells  
 Representative CD44, CD122 and CD62L expression profile of gated CD8+ T cells  
from spleen (A) and lymph nodes (B). Single cell suspensions from both spleen and 
lymph nodes were prepared and subsequently stained with CD44, CD122, CD62L 
antibodies. C) Single cell suspensions were prepared from both lymph nodes and 
spleens of SIT+/+  and SIT-/- mice. Subsequently, cells were stained with CD4, CD8, 
CD44 and CD25 antibodies. CD25 expression of gated CD8+CD44hi T cells is shown. 
Numbers in each quadrant indicate percentages. 
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2.5.3. Elevated CD5 expression in SIT-/- CD8+ T cells 
Peripheral T cells require signals generated by TCR:self-peptide-MHC interactions to 
survive and to undergo slow rate homeostatic proliferation. It is also worth mentioning 
that T cells carrying TCRs with stronger affinity have proliferation advantage in 
lymphopenic hosts as compared to cells expressing TCRs with lower affinity (48).  
Thus, an enhanced TCR-mediated signalling might also result in an enhanced 
homeostatic proliferation. To this end, I tested whether loss of SIT resulted in an 
increased TCR affinity in peripheral CD8+ T cells. Similar to thymocytes, also 
peripheral CD8+ T cells showed a significant upregulation of CD5 indicating that T 
cells in SIT-deficient mice indeed receive a permanently stronger signal via the TCR 
that might result in  an altered T-cell homeostasis (Figure 21, see also Figure 29A). 
 
 
 
Figure 21. Elevated CD5 expression level on SIT-deficient CD8+ T-cells 
Expression of CD5 on gated CD8+ T-cells. Lymph node and spleen cells were 
stained with CD8 and CD5 antibodies. Overlayed histograms show CD5 expression 
on  CD8+-gated SIT+/+ (shaded) and SIT-/- (empty) T-cells.  
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2.5.4. SIT-/- mice accumulate CD8+CD44hi T cells in secondary lymphoid 
organs 
We hypothesized that, SIT-/-CD8+ T cells acquire a memory-like phenotype upon 
enhanced homeostatic expansion, that would result in a corresponding accumulation 
of CD44high T cells in the periphery. Indeed, SIT-deficient mice progressively 
accumulated memory-like T cells in the spleen over the time as compared to wild-
type controls. This indicates that T-cell homeostasis is altered in SIT-/- mice (Figure 
22).  
 
 
 
 
 
 
 
Figure 22. Progressive accumulation of CD8+CD44high cells in SIT-deficient mice 
Absolute numbers of CD8+CD44high and CD4+CD44high T cells. Based on CD44 
expression absolute numbers of CD44low and CD44high cells were calculated within 
both CD4+ and CD8+ T-cell subsets. Means ±Standard Error of the Mean values 
(SEM) are shown in each graph. Empty triangles indicate SIT-knockout whereas 
filled squares represent wild-type mice. 
 
2.6. SIT regulates homeostatic proliferation of MHC-I-restricted TCR 
transgenic T cells 
2.6.1. Loss of SIT allows HY tg CD8+ T cells to undergo homeostatic 
proliferation in irradiated hosts  
To directly test the role of SIT in CD8+T-cell homeostasis, I adoptively transferred 
transgenic CD8+ T cells expressing TCRs with different affinities (HY, P14, OT-I) into 
irradiated recipients. Given the remarkable influence of SIT on positive selection in 
HY transgenic mice, first I decided to test whether SIT has also a strong influence on 
the homeostatic behaviour of peripheral HY T cells.  Strikingly, I found that SIT-/- 
HYCD8+ transgenic cells have undergone homeostatic expansion in lymphopenic 
hosts, whereas as reported SIT+/+ counterparts failed to do so (Figure 23). Similarly, 
loss of SIT resulted in an enhanced homeostatic proliferation also of P14 tg CD8+ T 
cells. Finally, I wished to test the homeostatic behaviour of OT-I CD8+ T cells that 
possess TCR with strong affinity. However, loss of SIT did not result in any alteration 
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in the homeostatic proliferation capacity  of OT-I CD8+ T cells in lymphopenic hosts 
(Figure 23). This is similar to the situation found in the thymus where thymic selection 
was also unaffected. Thus, SIT regulates T-cell homeostasis and development  in a 
strikingly similar manner. In conclusion, the ability of SIT to regulate TCR-mediated 
signalling is restricted to TCRs with low-intermediate affinities. 
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Figure 23.  SIT functions as a potent negative regulator of homeostatic 
proliferation of CD8+ T cells 
Homeostatic proliferation of adoptively transferred MHC-I restricted CD8+ transgenic 
T cells. A representative profile of multiple experiments is shown. CFSE-labelled 
lymph node cells from HY, P14 or OT-I SIT+/+CD45.2+or SIT-/-CD45.2+ transgenic 
mice were adoptively transferred into lethally irradiated CD45.1+ recipients. After 
seven (HY, P14) or 3 days (OT-I) cells were harvested and CFSE profiles of gated 
donor derived (CD45.1-) CD8+ T cells were analysed. Numbers shown above peaks 
indicate cell divisions. Histograms shown here represent four P14, four OT-I and at 
least six HY mice per each genotype. Gray bars indicate wild-type whereas empty 
bars represent SIT-/- mice. 
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2.6.2. SIT-/- HY transgenic CD8+ T cells undergo homeostatic proliferation in 
rag1-/- hosts  
 As a side effect of irradiation a strong cytokine storm is reported to occur (40, 84). 
The altered cytokine environment induced by irradiation might have induced 
homeostatic expansion of SIT-/- HY cells.  To rule out the possibility that the striking 
proliferation of SIT-/- HY transgenic cells was induced by an abnormal cytokine 
release triggered by irradiation, I injected CFSE-loaded LN cells from HY female 
mice into female Rag1-/- mice.  Peripheral lymphoid organs of rag1-/- deficient mice 
have a more physiological cytokine environment as compared to irradiated mice. As 
shown in figure 24, similar to irradiated recipients SIT-/-HYCD8+ T cells have 
undergone the same number of divisions also in rag1-/- hosts. Thus, we could 
exclude the possibility that the proliferation of SIT-/-HY+CD8+ T cells observed in 
irradiated hosts was due to an irradiation side effect. 
 
Figure 24. HY TCR tg T cells undergo homeostatic proliferation in rag1-/- mice 
Homeostatic proliferation of adoptively transferred HY transgenic CD8+ T cells. 
CFSE- labelled lymph node cells from HY CD45.2+ transgenic mice were adoptively 
transferred into lethally irradiated CD45.1+ recipients. After 7 days, injected cells were 
recovered and CFSE profiles of gated donor derived (CD45.1-) T3.70+ CD8+ T cells 
were analysed. Histograms shown here represent results of multiple experiments.  
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2.7. SIT-/- and SIT+/+ CD8+ T cells responded equally to cytokines in vitro 
Cytokines, mainly IL-7 and IL-15 play a major role in regulating homeostatic 
proliferation. To rule out the possibility that a different sensitivity to cytokines was 
responsible for the altered T-cell homeostasis in SIT-deficient mice, I investigated the 
ability of SIT+/+ and SIT-/- T cells to respond to cytokines in vitro. Total lymph node 
cells form SIT-/- and SIT+/+ mice were cultured  with or without cytokines for three 
days. As expected, IL-7 induced no proliferation of SIT+/+ and SIT-/- CD8+ T cells. 
Conversely, IL-15 induced a strong proliferation of CD8+ T cells. Nonetheless, I found 
no difference in the number of cell cycles induced by IL-15 between SIT+/+ and SIT-/- 
CD8+ T cells. Remarkably, quantitatively more CD8+ T cells responded to in vitro 
cytokine stimuli (Figure 25). This effect is most likely due to the higher proportion of 
CD44high cells within the CD8+ T cell subset in SIT-deficient mice (discussed above).  
  
 
 
 
 
 
 
 
Figure 25. SIT-/- CD8+ T cells show normal proliferation upon by cytokine 
stimulation in vitro 
Lymph node cells were isolated, loaded with CFSE and subsequently cultured for 
three days with cytokines (IL-7, IL-15) or left unstimulated. After three days, cells 
were harvested and stained with CD8 antibody and subsequently analysed by flow 
cytometry. Representative overlayed CFSE profiles of CD8+-gated SIT+/+ (shaded) 
and SIT-/- (empty) T cells are shown. 
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2.8. SIT-/- T cells are hyperresponsive to TCR stimulation in vitro  
2.8.1. Enhanced proliferation of SIT-deficient T cells in vitro 
So far, I have shown that loss of SIT affected T-cell development and homeostasis in 
vivo.  Next, I tested whether loss of SIT also affected T-cell function in vitro. To this 
end, I performed in vitro proliferation assays. Purified T cells derived either from 
SIT+/+ or from SIT-/- mice were stimulated with increasing concentrations of plate- 
bound CD3 antibody. After 72 hours, cells were harvested and subsequently [3H] 
thymidyne incorporation was determined. Figure 26A shows that SIT-/- T cells 
proliferated stronger especially when stimulated with suboptimal concentration of 
CD3. However, when stimulated with PMA both SIT+/+ and SIT-/- T cells showed equal 
proliferation. This indicates that SIT-/- T cells signal normally downstream of PKC 
(Figure 26A). In addition, upon CD3 stimulation SIT-/- T cells showed an elevated 
release of TH1 (T-helper 1) type cytokines indicating that absence of SIT skews 
peripheral T cells toward TH1 subset (Figure 26B).  
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Figure 26. SIT-/- T cells are hyperreactive and show elevated cytokine release  
A) Enhanced proliferation of SIT-deficient T cells. Purified splenic T cells were 
stimulated with plate-bound CD3 antibody or with PMA and ionomycin (bar graph) in 
96-well plates. Cells were pulsed with [3H]-thymidine and processed for standard 
scintillation counting. Graphs indicate results obtained from seven wild-type and nine 
SIT-knockout mice. Mean values are shown. One of two independent experiments is 
shown. p=0.01(*),P=0.007(**). B) Enhanced production of cytokines upon CD3 
stimulation. Purified T cells were stimulated either with plate- bound CD3 (0,3ug) or 
with PMA+ionomycin (P+I). Cytokine levels were determined from supernatants of 
stimulated cells. Results are obtained from eight wild-type and ten SIT-knockout 
mice. p=0.02(*), p<0.005(**). Black bars represent wild-type mice whereas empty 
bars indicate SIT-deficient mice. 
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2.8.2. SIT-deficient mice develop a more severe EAE 
SIT-deficient T cells have a lowered threshold of activation, an altered homeostasis, 
and are hyperreactive to TCR-mediated stimulation in vitro. Therefore, I wished to 
investigate whether SIT-deficient mice were more susceptible to develop 
autoimmune diseases. To this end, in collaboration with Dr. Dirk Reinhold, we used 
EAE (Experimental Autoimmune Enchephalitis) a well-established model of multiple 
sclerosis. As expected SIT-/- mice develop a faster as well as more severe EAE 
(Figure 27). In addition, aged SIT-knockout mice developed a spontaneous Lupus-
like disease and displayed an accumulation of activated CD4+ T cells in secondary 
lymphoid organs (Börge Arndt, et al. manuscript in preparation). Together, these data 
indicate that loss of SIT resulted in an enhanced susceptibility to develop 
autoimmunity.  
 
Figure 27. SIT-/- mice develop a more severe EAE  
EAE scores of SIT+/+ and SIT-/- mice. Mice were examined daily for the signs of EAE 
and graded on a scale of increasing severity from 0 to 5 as follows: 0 no signs, 0.5 
partial tail weakness, 1 limp tail or slight slowing of righting from supine position, 1.5 
limp and tail and slight slowing of righting, 2, partial hind limb weakness or marked 
slowing of righting, 2.5 dragging of hind limb(s), without complete paralysis, 3, 
complete paralysis of at least one hind limb, 3.5 hind limb paralysis and slight 
weakness of forelimbs, 4 severe forelimb paralysis, 5 moribund or death. EAE 
experiments and scoring were performed by Dr. Dirk Reinhold. 
 
   Days after immunisation 
E
A
E
 s
c
o
re
 (
m
e
a
n
±
S
E
M
) 
10      20    30 40  0 
  2.0 
1.5 
1,0 
0,5 
0,0 
EAE Scores 
SIT
+/+ 
SIT
-/- 
 54 
2.9. Sensory adaptation in SIT-/- CD8+ T cells 
Downregulation of CD8 is a mechanism that allows T cells to regulate the activation 
threshold. This could be required to counterbalance the effects of chronic stimulation 
(59).  As SIT-deficient T cells are hyperactivated they likely develop compensatory 
mechanisms similar to sensory adaptation that prevents them from becoming fully 
activated. This mechanism could help to maintain an efficient and controllable 
immune response. Indeed, when challenged with Toxoplasma or Listeria, SIT 
knockout mice showed a normal immune response. In addition, SIT-deficient mice 
showed a normal allograft rejection (unpublished observations from our laboratory). 
To test whether SIT-/- T cells develop sensory adaptation  I analysed the expression 
level of both CD4 and CD8 coreceptors. Indeed, I found a significant downregulation 
of the CD8 coreceptor already in SIT-/- mice (Figure 28A). In agreement with this 
observation, a marked CD8 coreceptor downregulation was also observed in both HY 
and P14 transgenic mice.  Downregulation of the CD8 resulted in accumulation of 
CD4-CD8- TCR transgenic T cells in the periphery of TCR transgenic HY and P14 
mice (Figure 28B). Additionally, SIT-/-CD8+ T cells express higher levels of CD5 
(Figure 28A and discussed above) a potent negative regulator of TCR-mediated 
signalling. Taken together, SIT-/- mice developed a mechanism similar to sensory 
adaptation in order to dampen TCR mediated signalling intensity. This mechanism 
likely in cooperation with others, prevents CD8+ T cells lacking SIT from becoming 
fully activated, thus allowing SIT-deficient mice to mount a controlled immune 
response when challenged with pathogens. However, the compensatory mechanism 
is only partially successful since SIT mice are more susceptible to EAE (see above) 
as well as develop activated  CD4+ T cells at the age of one year (Börge Arndt et al., 
manuscript in preparation). 
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Figure 28. Sensory adaptation in SIT-/-CD8+ T cells 
A) Expression of CD5 and CD8 on WT and SIT-deficient CD8+ T cells. Splenocytes 
were prepared and stained with CD5 and CD8 antibodies. Subsequently, flow 
cytometric analysis was carried out. The expression of CD5 (upper panel) and CD8 
(lower panel) on CD8+-gated T cells is shown. Table below indicates corresponding 
CD5 and CD8 MFI (mean fluorescence intensity) values. Statistical analyses were 
performed by using data obtained from 8 wild-type and 8 knockout mice. B) CD8 
coreceptor downregulation in HY and P14 mice. TCR transgenic mice were stained 
with CD4, CD8, and TCR (T3.70+ for HY and V2+ for P14) antibodies. Numbers of 
transgenic TCR+CD4-CD8- cells were calculated. 
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2.10. TCR-proximal signalling is impaired in SIT-/- mice at the level of 
Zap70 activation 
I next investigated TCR proximal signalling events in SIT-/- thymocytes and T cells. 
Thymocytes from SIT+/+ and SIT-/- mice were stimulated with crosslinked CD3 
antibody and subsequently lysed at the the indicated time points. Lysates were 
loaded on SDS PAGE and Western blot analysis was carried out. To assess global 
tyrosine phosphorylation in stimulated SIT-/- T cells, membranes were probed with 
anti p-Tyr (phospho-tyrosine) antibody. Surprisingly, we observed a general reduction 
of total Tyr phosphorylation in SIT-/- T cells. Strikingly, the phosphorylation of LAT 
(pp36-38) (Figure 29) was also severely impaired. Since LAT is known to be the 
substrate of the tyrosine kinase Zap-70, we have investigated whether Zap70 
activation was also impaired in SIT-deficient T cells.  To this end, wild-type and SIT- 
deficient thymocytes were stimulated with CD3 antibody, lysed and subsequently 
SDS PAGE was carried out. As figure 29 shows, Zap-70 phosphorylation as well as 
its kinase activity were strongly reduced in SIT-/- thymocytes. To further assess 
whether the severely impaired proximal signalling has any effect on more 
downstream signalling pathways such as MAPK activation we have also tested the 
level of phosphorylated ERK in SIT+/+ and SIT-/- thymocytes.  As figure 29 shows, the 
level of phosphorylated ERK was reduced in SIT-/- thymocytes as compared to wild-
type cells whereas JNK and P38 activation remained unaffected. 
Thus, proximal signalling events are severely impaired in SIT-deficient thymocytes. 
Moreover, further investigations revealed that similar to thymocytes, SIT-deficient 
peripheral T cells also show the same alteration of TCR-proximal signalling (Figure 
30). These data clearly indicate a presence of a strong compensatory mechanism(s) 
in SIT-/- T cells.  
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Figure 29. Reduced proximal signalling in SIT-deficient thymocytes 
Thymocytes were stimulated for the indicated times and assayed for the induction of 
total tyrosine phosphorylation (p-Tyr) or the activation of ERK1/2, JNK and p38. B) 
Thymocytes were stimulated and processed for immunoblotting. Phosphorylation of 
ZAP70 was analyzed by immunoblotting total post-nuclear cell lysates directly. 
ZAP70 immunoprecipitates were subjected to in vitro kinase assay. Experiment 
shown here was performed by Ines Meinert and Dr. Luca Simeoni. 
 
 
Figure 30. Reduced LAT phosphorylation upon CD3 stimulation of SIT-/- T cells 
Phosphorylation of LAT upon CD3 stimulation. A representative Western blot of three 
independent experiments is shown. Purified total T cells from spleen were stimulated 
with CD3 antibodies or left unstimulated. Subsequently, cells were lysed and SDS-
PAGE was carried out. Membranes were probed with p-Tyr (clone: 4G10) antibody. 
A phosphoprotein of 36-38 kDa protein corresponding to LAT is shown. Equal protein 
loading was assessed by reprobing the membrane with β-actin antibody. 
P-LAT (P-Tyr) 
  SIT+/+   SIT-/- 
0 1 5 15 30 0  1 5 15 30      CD3 min. 
β Actin 
pY319-ZAP-70 
anti-ZAP-70 
pY493-ZAP-70 
Total lysates 
IP: anti-ZAP-70 
IVK 
anti-ZAP-70 
 0     1      0   1    
SIT-/- SIT+/+ 
CD3 (min.)  0   1    5   15        0   1   5   15 
SIT-/- SIT+/+ 
p42 
p44 
p44
  
30 
45 
66 
97 
p-Tyr 
p46 
p46 
p54 
p38 
p38 
p-JNK 
JNK 
p-p38 
anti-p38 
p42 
p54 
p-ERK 
ERK 
 58 
Discussion 
Transmembrane adaptor proteins are key organizers of TCR-mediated signalling 
events. They recruit intracellular signalling proteins, thus serving as scaffolds to 
organize multisignalling complexes. In fact, TRAPs are essential to link the TCR to 
more downstream signalling events (41). By characterizing SIT-deficient mice, I 
showed that SIT regulates TCR-mediated processes such as T-cell development and 
T-cell homeostasis. 
SIT was previously shown to negatively regulate TCR-mediated signalling in Jurkat T 
cells (63, 85). In mice, SIT is expressed most abundantly in the thymus (Figure 6 and 
(103)). Therefore, I initially investigated the role of SIT in T-cell development. SIT- 
deficient mice display a higher percentage of DP and a decreased proportion of SP 
thymocytes. In addition, SIT-/- thymocytes have elevated levels of CD5 as well as 
CD69 as compared to wild-type cells (Figure 8). The upregulation of these two 
markers has been shown to correlate with the activation status of thymocytes (6, 7, 
73, 110). Thus, SIT-deficient thymocytes display a more activated phenotype 
(Figures 7-10). Moreover, SIT-deficient HY transgenic thymocytes display a more 
mature phenotype, a strongly reduced DP compartment and, elevated level of 
phosphorylated ERK, whose activation directly correlates with positive selection (3, 
87). Taken together, the more activated phenotype of SIT-deficient thymocytes, the 
strongly reduced proportion of DP thymocytes in HY mice, the more matured 
phenotype as well as the higher level of phosphorlated ERK, collectively demonstrate 
that loss of SIT results in an enhanced positive selection. It is likely that SIT lowers  
the activation threshold of thymocytes. In fact, SIT-knockout HY transgenic mice also 
showed a decreased thymocyte number demonstrating that, besides enhanced 
positive selection, a partial shift from positive to negative selection takes place in 
these mice (Figure 10). In agreement with these results, SIT-deficient mice 
expressing the P14 TCR with higher affinity displayed an almost  complete shift from 
positive to negative selection (Figure 10). Of importance, SIT-deficient HY male mice 
show an identical thymic cellular composition as compared to wild-type HY male 
mice ruling out the possibility that SIT would directly influence negative selection 
(Figure 12). Interestingly, T-cell development of both SIT deficient OT-I and OT-II 
mice was unaltered (Figure 11). This excludes the possibility that SIT would directly 
regulate apoptosis of thymocytes or the expression of CD5 or CD69. In addition the 
unaltered T-cell development in OT-I mice also indicates that SIT acts in a TCR 
affinity- dependent manner as beyond a certain TCR affinity it becomes dispensable. 
Moreover, SIT seems to influence mainly CD8+ T-cell development. However, the 
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role of SIT in the development of CD4+ T cells still needs to be further investigated by 
using other MHC-II restricted transgenic mouse models. Taken together, these 
results demonstrate that SIT functions as a negative regulator of TCR-mediated 
signalling in vivo. Indeed, mice lacking other negative regulators of TCR-mediated 
signalling such as CD5 show strikingly similar phenotype to SIT-deficient mice (6, 
114). As TRAPs have similar structures, it is likely that other TRAPs may 
compensate for the loss of SIT. TRIM, another non-raft associated transmembrane 
adaptor protein, displays structural homology and shares similar TBSMs with SIT 
(YGNL and YASV/L respectively). The fact that HY transgenic SIT/TRIM double-
knockout mice show a complete conversion from positive to negative selection 
strongly suggests that TRIM is indeed partially redundant with SIT during T-cell 
development (Uwe Kölsch et al., manuscript in preparation). Unlike TRIM, LAX 
(another non-raft associated TRAP) that similar to SIT possesses multiple Grb2 
binding sites does not seem to compensate for SIT in terms of T-cell development. 
This conclusion is drawn from the fact that LAX knockout mice do not show alteration 
of T-cell development and SIT/LAX double-knockout mice display the same alteration 
described in SIT-deficient mice (Börge Arndt et al., manuscript in preparation). Thus, 
among non-raft associated TRAPs, SIT and TRIM seem to be major regulators of T-
cell development.   
SIT is also strongly expressed by peripheral T cells ( Figure 6 and (103)). Based on 
its strong expression as well as its ability to set the threshold for thymocyte 
activation, we hypothesized that SIT would also influence peripheral T-cell functions. 
Investigation of peripheral lymphoid organs revealed that SIT-deficient mice have a 
reduced lymph node cellularity (Figure 14-15). More importantly, SIT-deficient mice 
progressively accumulate memory-like CD8+ T cells and display a reduction in the 
number of naïve CD8+ T cells both in lymph nodes and spleen (Figure 22). 
Interestingly, five month old SIT-deficient mice also accumulate memory-like CD4+ T 
cells. However, the CD4+ naïve T cell pool is unaltered in these mice. Thus, the CD8+ 
T-cell pool is more affected by the loss of SIT. The fact that SIT-deficient CD8+ T 
cells show comparable level of apoptosis, normal steady state proliferation as well as 
Bcl-2 expression (whose expression is crucial for T-cell survival) (14, 49, 72, 117) 
rules out the possibility that loss of SIT would result in an intrinsic survival or 
proliferation defect. We propose that SIT contributes to the maintenance of the 
peripheral T-cell pool, by controlling other mechanisms such as the threshold of T-
cell activation, generation of naïve T-cell precursors and T-cell homeostasis. SIT- 
knockout mice display a reduced proportion of CD103+ CD8+ T cells (Figure 16). 
CD103 has recently been reported as a marker of T cells with direct thymic origin 
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termed as recent thymic emigrants (65, 106). This result shows that SIT regulates the 
frequency of naïve T-cell precursors. Moreover, the progressive accumulation of 
memory-like T cells suggests that the slow rate peripheral T-cell homeostasis is also 
strongly altered by the loss of SIT. Peripheral T-cell homeostasis is responsible for 
maintaining constant peripheral T cell number during the course of life. This process 
is strongly dependent on low-affinity TCR:self-peptide-MHC interactions (13, 30, 47, 
64, 69, 77, 111, 113). Homeostatic proliferation is distinct from antigen driven 
proliferation since does not require costimulation. Moreover, T cells undergoing 
homeostatic expansion do not upregulate activation markers such as CD25 or CD69. 
It has been also shown that low-affinity peptides that mediate positive selection are 
also involved in controlling T-cell survival and homeostasis (30). Indeed, TCR 
transgenic mice possessing TCRs with different affinities display different abilities to 
undergo homeostatic proliferation when injected into lymphopenic hosts. In fact, T 
cells expressing TCR with a strong affinity have proliferative advantage over those 
expressing low-affinity TCRs (Figure 23 and (30, 48)). In line with these observations, 
HY transgenic T cells that possess low-affinity TCR are reported not to undergo 
homeostatic proliferation upon adoptive transfer into lymphopenic hosts (30, 35, 48). 
Strikingly, SIT-deficient HY transgenic CD8+ T cells do undergo lymphopenia-induced 
proliferation. Thus, loss of SIT resulted in the homeostatic expansion of HY tg T cells. 
Based on the same principle SIT deficiency resulted in a more pronounced 
homeostatic expansion of P14 transgenic T cells, thus SIT regulates TCR-mediated 
signalling strength (Figure 23).  
In summary, these results strongly and clearly demonstrate that SIT regulates both 
T-cell development and homeostasis in a strikingly similar manner. Other molecules 
such as BTLA or LAG3 have also been reported to regulate T-cell homeostasis 
without strongly altering the activation status of T cells. However, SIT is the only 
molecule that has been so far  shown to regulate both T-cell development and 
homeostasis in a strikingly similar fashion (52, 121). CD8+ T cells are more affected 
by the loss of SIT than CD4+ T cells. This observation can be explained by the fact 
that the homeostasis of CD8+ T cells is differentially regulated compared to those of 
CD4+ T cells. The fact that the adaptor protein GADS that is expressed in both CD8+ 
and CD4+ T cells has been also shown to selectively regulate CD4+ but not CD8+ T-
cell homeostasis further supports this view (124).  
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Collectively, our results demonstrate that SIT contributes to the maintenance of 
peripheral T-cell pools by at least two mechanisms. First, by regulating the number of 
T-cell precursors and second, by controlling peripheral T-cell homeostasis. The 
strong influence of SIT on both T-cell homeostasis and development is based on its 
ability to negatively regulate TCR-mediated signalling. Indeed, T cells from SIT 
deficient non-transgenic mice are hyperreactive upon TCR triggering in vitro (Figure 
27). In agreement with this observation, they also express higher levels of CD5, thus 
indicating that they permanently receive a stronger signal via the TCR (Figure 21). 
Based on our data, we propose that low affinity TCR: self-peptide-MHC mediated 
signals that usually promote T-cell survival become overtly stimulatory and induce a 
continuous low rate homeostatic expansion of T cells in SIT-deficient mice. During 
this expansion phase T cells would gradually acquire a memory-like phenotype. This 
mechanism together with the reduced numbers of T-cell precursors would also 
explain the decreased numbers of naïve CD8+ T cells.  
SIT-deficient T cells display both lowered thresholds of activation and impaired 
homeostasis. However, young SIT-deficient mice do not develop chronic 
inflammatory diseases. Hence, we propose the presence of compensatory 
mechanism(s) that prevent SIT-deficient T cells from becoming fully activated. 
Indeed, SIT-deficient T cells display signs similar to sensory adaptation such as CD8 
coreceptor downregulation or upregulation of CD5 (Figure 29 and (6, 7, 59, 104)). 
The strongly enhanced proportion of double negative T cells observed in both HY 
and P14 transgenic SIT-deficient mice further demonstrates the presence of sensory 
adaptation mechanisms induced by SIT-deficiency (Figure 28). Indeed, when 
investigated at the molecular level SIT-deficient thymocytes showed an impaired 
Zap70 kinase activity (Figure 29). Most likely a similar compensation mechanism is 
present in peripheral T cells as indicated by the strongly impaired LAT 
phosphorylation upon TCR triggering in vitro (Figure 30). However, the compensatory 
mechanism(s) seem(s) to be only partially efficient since aged SIT-/- mice develop a 
Lupus-like disease. (Börge Arndt et al, manuscript in preparation).  
SIT possesses five tyrosine-based signalling motifs that were shown to become 
phosphorylated upon TCR triggering in Jurkat T cells. Upon phosphorylation, TBSMs 
of SIT recruit molecules such as Grb2, SHP2, and Csk that are capable of regulating 
various intracellular signalling pathways (63, 85). Though upon TCR stimulation SIT 
recruits SHP2 via its ITIM motif, yet the negative regulatory effect of SIT in Jurkat 
cells is exclusively mediated via the YASV motif (63, 85). However, it can be that SIT 
functions differentially in primary mouse T cells. Thus, one has to consider that, 
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unlike Jurkat T cells where SIT might exert its negative regulatory function via the 
YASV motif, in primary mouse T cells the negative regulatory effect of SIT could be 
mediated via the ITIM motif and therefore could involve SHP-2.  This view is 
supported by the fact that mice lacking other negative regulatory molecules 
possessing ITIM motifs such as CD5, PD-1 and BTLA display a simiar phenotype to 
SIT-/- mice. Another possible mechanism is that SIT, by recruiting Grb2 upon TCR 
engagement, would sequester away this molecule from lipid rafts. Thus, the reduced 
availability of Grb2 would result in a reduced TCR mediated signalling strength. 
Detailed investigation of SIT-deficient mice have revealed that SIT is a potent 
regulator of multiple aspects of T-cell functions such as development, threshold of 
activation and homeostasis. These results highlight the role of TRAPs in regulating a 
wide spectrum of immune functions with clinical relevance. 
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Abbreviations 
aa   amino acid 
BSA  bovine serum albumin 
Csk   C-terminal Src kinase  
DMSO  dimethylsulfoxide 
DN   double negative 
DP   double positive 
EAE  experimental aoutimmune encephalomyelitis 
EDTA  ethylenediamine tetraacetic acid 
ERK  extracellular signal-regulated protein kinase 
FCS  fetal calf serum 
FITC  flourescein isotyocyanate 
Gads  Grb2 related adapter protein 
GEM  glycosphyngolipid-enriched microdomains 
Grb2  growth factor receptor binding protein 2 
ITAM  immunoreceptor tyrosine-based activation motif 
ITIM  immunoreceptor tyrosine-based inhibitory motif 
LAT   linker for activation of T cells 
LAX  linker for activation of X cells 
Lck   lymphocyte-specific cytoplasmic protein tyrosine kinase 
LIME  lck-interacting membrane protein 
MAPK  mytogen-activated kinase  
NFκB  nuclear factor κB 
NTAL  non-T cell activation linker 
PBS  phosphate-buffered saline 
PEP  PEST domain-enriched tyrosine phosphatase  
PI3K  phosphatidylinositol-3 kinase 
PLC  phospho lipase C 
SDS PAGE  SDS polyacryamid gel electrophoresis 
SH2  Src homology domain 2  
SHIP  SH2-domain containing inositol phosphatase 
SHP-1  Sh2 domain containing PTP 
SIT  SH2-domain-containing protein tyrosine phosphatise (SHP2)-
interacting transmembrane adaptor protein 
SLP-76  SH2 domain containing leucocyte protein of 76 kDa 
SOS  son of sevenless homolouge 
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SP   single positive 
Src   Src homology  
TBSM  tyrosine based signalling motif 
TCR  T cell receptor 
Tg   transgenic 
TN   triple negative 
TRAP  transmembrane adaptor protein 
TRIM  TCR interacting transmembrane adaptor protein 
VAV  guanine nucleotide exchange factor 
Zap70  zeta associated protein of 70 kDa 
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Appendix I. 
Antibodies used in this study 
FACS 
 
Antibody Fluorophore Cat.Nr. Company 
CD8 FITC 553031 BD 
CD8 PE 553033 BD 
CD8 CyCh 553034 BD 
CD8 APC 553035 BD 
CD4 FITC 553055 BD 
CD4 PE 553049 BD 
CD4 CyCh 553050 BD 
CD4 APC 553051 BD 
CD5 FITC 553021 BD 
CD5 APC 550035 BD 
βTCR FITC 553171 BD 
βTCR PE 553172 BD 
βTCR CyCh 553173 BD 
aCD3 FITC 553062 BD 
αCD3 PE 553064 BD 
αCD3 CyCh 553065 BD 
aCD3 APC 553066 BD 
CD44 PE 553134 BD 
CD44 CyCh 553135 BD 
CD69 PE 553237 BD 
CD122 PE 553362 BD 
CD62Li PE 553151 BD 
CD25 PE 553866 BD 
CD45.1 PE 553776 BD 
CD45.2 FITC 553772 BD 
Vα2 TCR FITC 553288 BD 
T3.70 FITC 11-99-30-85 Bioscience 
T3.70-biotin  11-99-30-82 Bioscience 
αBRDU FITC 36634K BD  
αBRDU-
Isotype 
FITC  BD 
Annexin-V PE 556421 BD 
Bcl-2 (Kit) FITC 554221 BD 
Bcl-2 
Isotype (Kit) 
FITC 554221 BD 
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Appendix II 
Antibody Conjugate Clone Company 
CD3 biotin 145-2C11 BD 
CD4 - GK1.5 BD 
CD28 - 37.51 BD 
LAT - - Transduction 
Lab. 
Zap70 -  Santa Cruz 
P-Tyr - 4G10 - 
p-ERK - - Cell 
Signalling 
p-JNK - - Cell 
Signalling 
p-P38 - - Cell 
Signalling 
P38 - - Cell 
Signalling 
p-LAT(Y171, 
Y191) 
- - Cell 
Signalling 
p-LAT 
(Y226) 
- - Upstate 
LAT - - Gift from 
Dr.Weiguo 
Zhang 
p-Zap70 
(Y319, 
Y293) 
- - Cell 
Signalling 
Zap 70 - - Transduction 
Laboratories 
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Appendix III 
PCR programs and master mixes used for genotyping 
program    SIT    master mix 25µl 
        
1=94C° 1 min       genomic DNA  1.5ul 
2=94C° 40 sec       Primer 1 (50pmol/µl) 0.2µl 
3=65C° 1 min       Primer 2 (50pmol/µl) 1.1µl 
4=72 C° 1 min       Primer 3 (50pmol/µl) 1.0µl 
5=Go to 2 29 times      dNTP (20µM each) 0.25µl 
6=72C° 3 min       10x Buffer   2.5µl 
7=4C° for ever       Taq polym.   0.2µl 
         H20    18.25µl 
 
program    HY    master mix 25µl 
         
1=94C° 3 min       genomic DNA  1.5µl 
2=94C° 30 sec       Primer 1 (50pmol/µl) 1.0µl 
3=60C° 45 sec       Primer 2 (50pmol/µl) 1.0µl 
4=72 C° 45 sec       dNTP (20µM each) 0.25µl 
5=Go to 2 25 times      10xBuffer   2.5µl 
6=72C° 10 min       Taq polym.   0.2µl 
7=4C° for ever       H20    18.55µl 
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program    P14    master mix 25µl 
  
1=94C° 1 min       genomic DNA  1.5ul 
2=94C° 30 sec       Primer 1 (50pmol/µl) 0.5µl 
3=55C° 30 sec       Primer 2 (50pmol/µl) 0.5µl 
4=72 C° 1.30 min      dNTP (20µM each) 0.25µl 
5=Go to 2 30 times      10xBuffer   2.5µl 
6=4C° for ever       MgCl2   0,225µl 
         Taq ploym.   0.2µl 
         H20    20,82 µl 
 
program    OT-I   master mix 25µl 
 
1=94C° 3 min       genomic DNA  1.5µl 
2=94C° 30 sec       Primer 1   0.25µl 
3=52C° 30 sec       Primer 2   0.25µl 
4=72 C° 30 sec       Primer 3   0.125µl 
5=Go to 2 39 times      Primer 4   0.125µl 
6=72C° 2 min       10xBuffer   2.5µl 
7=4C° for ever       5xEnhancer Q  5.0µl 
         Taq polymerase  0.5µl 
         H2O    14.5µl 
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program    Rag1    master mix 25µl 
 
1=94C° 3 min       genomic DNA  1.5ul 
2=94C° 0.30 min       Primer 1: (50pmol/µl) 0.5µl 
3=55C° 1 min       Primer 2: (50pmol/µl) 0.2µl 
4=72C° 1 min       Primer 3: (50pmol/µl) 0.2µl 
5=Go to 2 35 times      dNTP (20µM each)  0.25µl 
6=72C° 2 min       10xBuffer:   2.5µl 
7=4C° for ever       Taq polym.   0.13µl 
         H20    17.7µl 
 
program    Fyn     master mix 25µl 
 
1=94C° 3 min       genomic DNA  1,5µl  
2=94C° 30 sec       Primer 1: (50pmol/µl) 0.5µl 
3=60C° 45 sec       Primer 2: (50pmol/µl) 0.5µl 
4=72C° 45 sec       Primer 3: (50pmol/µl) 0.5µl 
5=Go to 2 30 times      Primer 4: (50pmol/µl) 0.5µl 
6=72C° 10 min       dNTP (20µM each) 0.25µl 
7=4C° for ever       10xBuffer   2.5µl 
         DMSO:   1.25µl 
         H20    14.8µl 
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